A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
An alternative to amputation in patients with neoplasms, ischemia, fractures, and other limb-threatening conditions. Generally, sophisticated surgical procedures such as vascular surgery and reconstruction are used to salvage diseased limbs.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
The return of a sign, symptom, or disease after a remission.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Transplantation of an individual's own tissue from one site to another site.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Vomiting caused by expectation of discomfort or unpleasantness.
Antibodies obtained from a single clone of cells grown in mice or rats.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Infections with fungi of the genus ASPERGILLUS.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Partial or total surgical excision of the tongue. (Dorland, 28th ed)
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Recovery of blood lost from surgical procedures for reuse by the same patient in AUTOLOGOUS BLOOD TRANSFUSIONS. It is collected during (intraoperatively) or after completion of (postoperatively) the surgical procedures.
An anti-inflammatory 9-fluoro-glucocorticoid.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
Infection in humans and animals caused by fungi in the class Zygomycetes. It includes MUCORMYCOSIS and entomophthoramycosis. The latter is a tropical infection of subcutaneous tissue or paranasal sinuses caused by fungi in the order Entomophthorales. Phycomycosis, closely related to zygomycosis, describes infection with members of Phycomycetes, an obsolete classification.
Ester of CHLORAMBUCIL and PREDNISOLONE used as a combination alkylating agent and synthetic steroid to treat various leukemias and other neoplasms. It causes gastrointestinal and bone marrow toxicity.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation.
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
The removal of a limb or other appendage or outgrowth of the body. (Dorland, 28th ed)
Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE).
Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS.
Triazoles are a class of antifungal drugs that contain a triazole ring in their chemical structure and work by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting the integrity and function of the membrane.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Elements of limited time intervals, contributing to particular results or situations.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Therapy with two or more separate preparations given for a combined effect.
An anthracenedione-derived antineoplastic agent.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Pyrimidinones are heterocyclic organic compounds that consist of a pyrimidine ring fused with a ketone group, which have significant applications in medicinal chemistry due to their wide range of biological activities, including antibacterial, antiviral, and anticancer properties.
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
Pyrazines are heterocyclic organic compounds containing a six-membered ring with two nitrogen atoms at opposite positions, often responsible for the characteristic flavors and aromas found in various foods, beverages, and some biological systems, but they do not have a direct medical definition as they are not a drug, treatment, or a significant component of human physiology or pathology.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.
Carbon-containing phosphonic acid compounds. Included under this heading are compounds that have carbon bound to either OXYGEN atom or the PHOSPHOROUS atom of the (P=O)O2 structure.
Tumors or cancer of the PROSTATE.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
The degree to which BLOOD VESSELS are not blocked or obstructed.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Antibodies produced by a single clone of cells.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
The inferior part of the lower extremity between the KNEE and the ANKLE.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The anterior and posterior arteries created at the bifurcation of the popliteal artery. The anterior tibial artery begins at the lower border of the popliteus muscle and lies along the tibia at the distal part of the leg to surface superficially anterior to the ankle joint. Its branches are distributed throughout the leg, ankle, and foot. The posterior tibial artery begins at the lower border of the popliteus muscle, lies behind the tibia in the lower part of its course, and is found situated between the medial malleolus and the medial process of the calcaneal tuberosity. Its branches are distributed throughout the leg and foot.
Leukopenia is a condition characterized by an abnormally low white blood cell count (less than 4,000 cells per microliter of blood) in peripheral blood, increasing the risk of infection due to decreased immune defense.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
An organoplatinum compound that possesses antineoplastic activity.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
A decrease in the number of NEUTROPHILS found in the blood.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Reinfusion of blood or blood products derived from the patient's own circulation. (Dorland, 27th ed)
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Antimetabolites that are useful in cancer chemotherapy.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.
The region of the lower limb in animals, extending from the gluteal region to the FOOT, and including the BUTTOCKS; HIP; and LEG.
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.

Second-line treatment for primary central nervous system lymphoma. (1/1778)

Failure after first-line treatment was reported in 35-60% of immunocompetent patients with primary central nervous system lymphoma (PCNSL). There are currently no reports focusing on salvage therapy. This review analyses prognostic factors and the efficacy of salvage therapy by focusing on data from papers reporting results of first-line treatment in 355 cases. The study group consisted of 173 patients presenting treatment failure. The interval between failure and death (TTD) was compared for age at relapse (< or =60 vs. >60 years), type of failure (relapse vs. progression), time to relapse (< or =12 vs. >12 months) and salvage treatment (yes vs no). Median TTD was similar in younger and older patients (P = 0.09). Relapsed patients had a longer TTD than patients with progressive disease (P = 0.002). Early relapse led to a shorter TTD than late relapse (P = 0.005). Median TTD was 14 months for patients who underwent salvage therapy and 2 months for untreated cases (P<0.00001). A multivariate analysis showed an independent prognostic role for salvage therapy and time to relapse. Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule.  (+info)

ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience. (2/1778)

BACKGROUND: The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C) and cisplatin, has been shown to be active against refractory non-Hodgkin's lymphoma in therapeutic trials. We were interested in determining whether this regimen would be effective and tolerable for Chinese patients. METHODS: Thirty-two patients with refractory/relapsed non-Hodgkins lymphoma (23 intermediate-grade and nine high-grade) were enrolled in this study. Etoposide was administered at a dose of 40 mg/m2/day as a 1 h intravenous infusion from day 1 to day 4, solumedrol 500 mg/day was given as a 15 min intravenous infusion from day 1 to day 5, ara-C 2 g/m2 was given as a 2 h intravenous infusion on day 5 and cisplatin was given at a dose of 25 mg/m2/day as a continuous infusion from day 1 to day 4. Clinical efficacy and toxicity were assessed on the basis of the WHO criteria. RESULTS: Ten patients (31.3%, 95% Cl 15.2-47.4%) attained complete remission (CR) and seven had partial remission (PR). The overall response rate was 53.1% (95% Cl 35.8-70.4%). In eight of the 10 CR patients, the remission lasted for more than 8 months. The remaining two patients had CR of 5 and 6 months. The median duration of CR was 12.2 months (range 5-22 months). Myelosuppression with subsequent infections was the major toxicity. Severe leukopenia (WBC < 1000/microliter) lasted for an average of 12 days and thrombocytopenia (< 25,000/microliter) 18 days. One patient (3.1%) died of neutropenia-associated sepsis within 4 weeks after treatment. Non-myeloid toxicities included alopecia in 66% (28% grade 2, 22% grade 3), stomatitis in 72% (25% grade 2, 28% grade 3, 13% grade 4), hepatotoxicity in 9% (3% grade 2), renal toxicity in 13% (6% grade 2, 3% grade 3) and infection in 56% (18% grade 2, 25% grade 3, 13% grade 4). The majority of the responders relapsed within 2 years after ESHAP treatment. Median survival for all patients was 8.6 months. CONCLUSIONS: ESHAP is an active and tolerable regimen in Chinese patients with relapsed/refractory lymphoma, but the duration of remission is brief and without significant impact on survival.  (+info)

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. (3/1778)

Transplantation after high-dose chemotherapy prolongs survival in patients with multiple myeloma compared with standard therapy. It is unclear whether the optimal timing of transplantation is immediately after induction chemotherapy or whether stem cells may be cryopreserved for transplantation at subsequent progression or relapse. In this study, stem cells were collected within 6 months of diagnosis, followed by transplantation only at progression of myeloma. One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved. Eleven had transplants early in the disease after they demonstrated failure to respond to primary therapy. The remaining 107 were eligible for transplants when there was evidence of progressive disease. Of the 118 patients, 67 had transplants, nine died of progressive disease before transplantation, and 42 remain alive in plateau phase. The median survival of the group is 58.5 months; 67 are alive. Serum beta2-microglobulin, bone marrow labeling index (S phase), and hemoglobin level predicted overall survival (P < 0.006, P < 0.001, and P < 0.01, respectively). We conclude that early cryopreservation of blood stem cells followed by transplantation at progression is a feasible approach to therapy in patients with myeloma. The underlying biology of the disease has a greater impact on survival than the timing of transplantation. A prospective randomized trial is required to answer definitively the question of the optimal timing of blood cell transplantation.  (+info)

High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. (4/1778)

Between 1985 and 1996, 51 patients with relapsed or refractory small cleaved cell lymphoma (SCCL) received high-dose chemotherapy +/- TBI in conjunction with autologous (ABMT) (36 patients) or allogeneic transplantation (15 patients). Patients were eligible for ABMT if the bone marrow biopsy done prior to the planned transplant did not reveal microscopic involvement with SCCL. Patients receiving ABMT had a median age of 48 years, had received a median of 2.5 chemotherapy regimens prior to transplantation, and were transplanted a median of 35.5 months from diagnosis. Among patients receiving ABMT, 5 year actuarial survival was 56+/-11%. Median survival was 126+ months, and median survival from diagnosis was 191 months. Univariate and multivariate analysis identified sensitive disease as the best predictor of a favorable response. Five-year actuarial survival was 66+/-12% for patients with sensitive disease at the time of transplant as compared to 29+/-17% for patients with resistant disease, P = 0.015. Median survival in patients with sensitive disease at the time of ABMT was 126+ months. By univariate analysis, survival was significantly better for patients receiving ABMT as compared to patients receiving allogeneic transplants. Median survival following allogeneic transplantation was 5 months; 5 year actuarial survival was 15+/-13%. In a multivariate analysis, which considered autologous vs allogeneic transplantation, sensitive vs resistant disease, <3 vs > or = 3 prior treatments, and prior bone marrow involvement, allogeneic transplantation was significantly associated with poor survival. Treatment-related mortality occurred in eight of 15 patients receiving allogeneic transplantation and limited the effectiveness of this therapy. High-dose therapy in conjunction with ABMT is effective therapy for patients with SCCL whose disease is sensitive to chemotherapy and whose marrows are microscopically free of disease. Because of possible selection bias, it has not been proven that this approach increases survival in these patients. Treatment-related mortality limits the effectiveness of allogeneic transplantation in SCCL.  (+info)

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. (5/1778)

We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells. Based on these data a pilot study on autologous transplantation of NM/VP-16 purged PBSC for high-risk leukemic patients was recently initiated. Twelve patients (seven females and five males) with a median age of 46 years (range 18-57) have been treated. Two patients had acute myeloblastic leukemia (AML) resistant to conventional induction treatment, four patients had secondary AML in I complete remission (CR), one patient was in II CR after failing a previous autologous BM transplantation, while two additional AML individuals were in I CR achieved after three or more cycles of induction treatment. Two patients with high-risk acute lymphoblastic leukemia (ALL) in I CR and one patient with mantle cell lymphoma and leukemic dissemination were also included. Eight patients showed karyotypic abnormalities associated with a poor clinical outcome. The mobilizing regimens included cytosine arabinoside and mitoxantrone with (n = 6) or without fludarabine (n = 3) followed by subcutaneous administration of G-CSF (5 microg/kg/day until the completion of PBSC collection) and G-CSF alone (n = 3) (15 microg/kg/day). A median of two aphereses (range 1-3) allowed the collection of 7.2 x 10(8) TNC/kg (range 3.4-11.5), 5 x 10(6) CD34+ cells/kg (range 2.1-15.3) and 9.2 x 10(4) CFU-GM/kg (0.3-236). PBSC were treated with a constant dose of 20 microg of VP-16/ml and a median individual-adjusted dose (survival < or = 5% of steady-state BM CFU-GM) of NM of 0.7 microg/ml (range 0.25-1.25). Eleven patients were reinfused after busulfan (16 mg/kg) and Cy (120 mg/kg) conditioning with a median residual dose of 0.3 x 10(4) CFU-GM/kg (0-11.5). The median time to neutrophil engraftment (>0.5 x 10(9)/l) for evaluable patients was 25 days (range 12-59); the median time to platelet transfusion independence (>20 and >50 x 10(9)/l) was 40 days (18-95) and 69 days (29-235), respectively. Hospital discharge occurred at a median of 25 days (18-58) after stem cell reinfusion. Four individuals are alive in CR (n = 3) or with residual nodal disease (n = 1 lymphoma patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died due to disease progression or relapse (n = 5) or extrahematological transplant toxicity (n = 2). Our data suggest that pharmacological purging of leukapheresis collections of leukemic patients at high-risk of relapse is feasible and ex vivo treated cells reconstitute autologous hematopoiesis.  (+info)

Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. (6/1778)

Allogeneic bone marrow transplantation (BMT) is a common treatment of hematologic malignancies. Recurrence of the underlying malignancy is a major cause of treatment failure. Donor-derived cytotoxic T lymphocytes (CTLs) specific for patients' minor histocompatibility antigens (mHags) play an important role in both graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) reactivities. mHags HA-1 and HA-2 induce HLA-A*0201-restricted CTLs in vivo and are exclusively expressed on hematopoietic cells, including leukemic cells and leukemic precursors, but not on fibroblasts, keratinocytes, or liver cells. The chemical nature of the mHags HA-1 and HA-2 is known. We investigated the feasibility of ex vivo generation of mHag HA-1- and HA-2-specific CTLs from unprimed mHag HA-1- and/or HA-2-negative healthy blood donors. HA-1 and HA-2 synthetic peptide-pulsed dendritic cells (DCs) were used as antigen-presenting cells (APC) to stimulate autologous unprimed CD8(+) T cells. The ex vivo-generated HA-1- and HA-2-specific CTLs efficiently lyse leukemic cells derived from acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) patients. No lytic reactivity was detected against nonhematopoietic cells. Sufficient numbers of the CTLs can be obtained for the adoptive immunotherapy purposes. In conclusion, we present a feasible, novel therapy for the treatment for relapsed leukemia after BMT with a low risk of GVHD.  (+info)

Treatment of multiple myeloma. (7/1778)

BACKGROUND AND OBJECTIVE: Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies. The standard treatment with intermittent courses of melphalan and prednisone (MP) was introduced more than 30 years ago and, since then there has been little improvement in event-free and overall survival (EFS & OS). The aim of this article is to review: 1) the role of initial chemotherapy (ChT), maintenance treatment with alpha-interferon and salvage ChT, 2) the results of high-dose therapy (HDT) followed by allogeneic or autologous stem cell transplantation (allo-SCT and auto-SCT), and 3) the most important supportive measures. EVIDENCE AND INFORMATION SOURCES: The authors of this review have been actively working and contributing with original investigations on the treatment of MM during the last 15 years. In addition, the most relevant articles and recent abstracts published in journals covered by the Science Citation Index and Medline are also reviewed. STATE OF THE ART AND PERSPECTIVES: The importance of avoiding ChT in asymptomatic patients (smoldering MM) is emphasized. The criteria and patterns of response are reviewed. MP is still the standard initial ChT with a response rate of 50-60% and an OS of 2-3 years. Combination ChT usually increases the response rate but does not significantly influence survival when compared with MP. Exposure to melphalan should be avoided in patients in whom HDT followed by auto-SCT is planned, in order to not preclude the stem cell collection. The median response duration to initial ChT is 18 months. Interferon maintenance usually prolongs response duration but in most studies does not significantly influence survival (a large meta-analysis by the Myeloma Trialists' Collaborative Group in Oxford is being finished). In alkylating-resistant patients, the best rescue regimens are VBAD or VAD. In patients already resistant to VBAD or VAD and in those in whom these treatments are not feasible we recommend a conservative approach with alternate day prednisone and pulse cyclophosphamide. While HDT followed by autotransplantation is not recommended for patients with resistant relapse, patients with primary refractory disease seem to benefit from early myeloablative therapy. Although results from large randomized trials are still pending in order to establish whether early HDT intensification followed by auto-SCT is superior to continuing standard ChT in responding patients, the favorable experience with autotransplantation of the French Myeloma Intergroup supports this approach. However, although the complete response rate is higher with intensive therapy, the median duration of response is relatively short (median, 16 to 36 months), with no survival plateau. There are several ongoing trials comparing conventional ChT with HDT/autoSCT in order to identify the patients who are likely to benefit from one or another approach. With allo-SCT there is a transplant-related mortality ranging from 30 to 50% and also a high relapse rate in patients achieving CR. However, 10 to 20% of patients undergoing allo-SCT are long-term survivors (> 5 years) with no evidence of disease and, consequently, probably cured. The use of allogeneic peripheral blood stem cells (PBSC) in order to speed the engraftment and also the use of partially T-cell depleted PBSC which can decrease the incidence of graft-versus-host disease are promising approaches. In the setting of allo-SCT, donor lymphocyte infusion is an encouraging strategy in order to treat or prevent relapses. Finally, important supportive measures such as the treatment of anemia with erythropoietin, the management of renal failure and the use of bisphosphonates are reviewed.  (+info)

Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital. (8/1778)

BACKGROUND AND OBJECTIVE: Analysis of costs of high technological procedures such as peripheral blood stem cell (PBSC) autotransplantation in lymphomas are generally finalized at disclosing whether the improvement of survival in a subset of patients is cost effective and whether the cost of the procedure could be reduced. With the aim of revealing a possibility of reducing costs with respect to conditions of safety, we present our experience with PBSC autotransplantation in a particularly poor prognosis subset of patients with lymphoma. DESIGN AND METHODS: The expenses are analyzed for groups of cost and main resources necessary at unitary cost are considered separately. Groups of cost include various phases of the PBSC autotransplantation such as preparative procedures, execution of myeloablative therapy, reinfusion of CD34 cells, supportive therapy after reinfusion until discharge of the patient, general support for the management of patient. All costs are calculated according to 1997 prices and salaries and reported in dollars. The analysis was conducted on 21 patients with lymphoma resistant to other therapies treated by myeloablative therapy and PBSC autotransplantation in an hematologic unit in an open ward; the assistance was provided by staff not exclusively dedicated to bone marrow transplant procedures, with some help from a family member. RESULTS: The PBSC procedure, including all phases, costs from $17,761.9 to $18,259.9 depending on the type of myeloablative therapy employed; the mean cost was $18,092.6. The preparative phase with mobilization of CD34 cells, cryopreservation and reinfusion costed $3,538.7 (19.6% of the total cost); a major cost of this phase was cryopreservation and CD34 manipulation ($857.1). The second phase with myeloablative therapy and reinfusion of CD34 cells had a mean cost of $2,785.9 (15.4% of the total cost); a major cost of this phase was the hospitalization ($1,119.8). The third phase of patient's support after treatment had a total cost of $7,649 (42.3% of the cost of the total procedure) with the major cost being due to hospitalization ($2,571) calculated on a mean of 15 days after the reinfusion of CD-34. The last group of costs, including management support, accounted for $4,119 (22.7%) with a major cost being amortization of the structure ($1,600). The general cost for nurse's assistance to the patient was $1,355.1 (7.5%). INTERPRETATION AND CONCLUSIONS: A procedure of PBSC autotransplantation in resistant lymphoma is affordable without the strict precautions generally given in intensive care units. This provides a substantial reduction of expenses because of the low number of specifically trained staff members and the generally low cost of the necessary supplies. Before, however, proposing PBSC autotransplantation in most patients with resistant lymphoma, an evaluation of whether costs could be further reduced and whether the procedure has a cost benefit impact is needed.  (+info)

Salvage therapy, in the context of medical oncology, refers to the use of treatments that are typically considered less desirable or more aggressive, often due to greater side effects or lower efficacy, when standard treatment options have failed. These therapies are used to attempt to salvage a response or delay disease progression in patients with refractory or relapsed cancers.

In other words, salvage therapy is a last-resort treatment approach for patients who have not responded to first-line or subsequent lines of therapy. It may involve the use of different drug combinations, higher doses of chemotherapy, immunotherapy, targeted therapy, or radiation therapy. The goal of salvage therapy is to extend survival, improve quality of life, or achieve disease stabilization in patients with limited treatment options.

Limb salvage is a medical term used to describe the surgical procedures and treatments aimed at preserving and restoring the functionality of a severely injured or diseased limb, rather than amputating it. The goal of limb salvage is to improve the patient's quality of life by maintaining their mobility, independence, and overall well-being.

Limb salvage may involve various surgical techniques such as vascular reconstruction, bone realignment, muscle flap coverage, and external fixation. These procedures aim to restore blood flow, stabilize bones, cover exposed tissues, and prevent infection. Additionally, adjuvant therapies like hyperbaric oxygen treatment, physical therapy, and pain management may be employed to support the healing process and improve functional outcomes.

Limb salvage is typically considered when a limb is threatened by conditions such as severe trauma, tumors, infections, or peripheral arterial disease. The decision to pursue limb salvage over amputation depends on factors like the patient's overall health, age, and personal preferences, as well as the extent of the injury or disease, potential for recovery, and likelihood of successful rehabilitation.

Antineoplastic combined chemotherapy protocols refer to a treatment plan for cancer that involves the use of more than one antineoplastic (chemotherapy) drug given in a specific sequence and schedule. The combination of drugs is used because they may work better together to destroy cancer cells compared to using a single agent alone. This approach can also help to reduce the likelihood of cancer cells becoming resistant to the treatment.

The choice of drugs, dose, duration, and frequency are determined by various factors such as the type and stage of cancer, patient's overall health, and potential side effects. Combination chemotherapy protocols can be used in various settings, including as a primary treatment, adjuvant therapy (given after surgery or radiation to kill any remaining cancer cells), neoadjuvant therapy (given before surgery or radiation to shrink the tumor), or palliative care (to alleviate symptoms and prolong survival).

It is important to note that while combined chemotherapy protocols can be effective in treating certain types of cancer, they can also cause significant side effects, including nausea, vomiting, hair loss, fatigue, and an increased risk of infection. Therefore, patients undergoing such treatment should be closely monitored and managed by a healthcare team experienced in administering chemotherapy.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Hodgkin disease, also known as Hodgkin lymphoma, is a type of cancer that originates in the white blood cells called lymphocytes. It typically affects the lymphatic system, which is a network of vessels and glands spread throughout the body. The disease is characterized by the presence of a specific type of abnormal cell, known as a Reed-Sternberg cell, within the affected lymph nodes.

The symptoms of Hodgkin disease may include painless swelling of the lymph nodes in the neck, armpits, or groin; fever; night sweats; weight loss; and fatigue. The exact cause of Hodgkin disease is unknown, but it is thought to involve a combination of genetic, environmental, and infectious factors.

Hodgkin disease is typically treated with a combination of chemotherapy, radiation therapy, and/or immunotherapy, depending on the stage and extent of the disease. With appropriate treatment, the prognosis for Hodgkin disease is generally very good, with a high cure rate. However, long-term side effects of treatment may include an increased risk of secondary cancers and other health problems.

Remission induction is a treatment approach in medicine, particularly in the field of oncology and hematology. It refers to the initial phase of therapy aimed at reducing or eliminating the signs and symptoms of active disease, such as cancer or autoimmune disorders. The primary goal of remission induction is to achieve a complete response (disappearance of all detectable signs of the disease) or a partial response (a decrease in the measurable extent of the disease). This phase of treatment is often intensive and may involve the use of multiple drugs or therapies, including chemotherapy, immunotherapy, or targeted therapy. After remission induction, patients may receive additional treatments to maintain the remission and prevent relapse, known as consolidation or maintenance therapy.

Treatment failure is a term used in medicine to describe the situation when a prescribed treatment or intervention is not achieving the desired therapeutic goals or objectives. This may occur due to various reasons, such as:

1. Development of drug resistance by the pathogen or disease being treated.
2. Inadequate dosage or frequency of the medication.
3. Poor adherence or compliance to the treatment regimen by the patient.
4. The presence of underlying conditions or comorbidities that may affect the efficacy of the treatment.
5. The severity or progression of the disease despite appropriate treatment.

When treatment failure occurs, healthcare providers may need to reassess the patient's condition and modify the treatment plan accordingly, which may include adjusting the dosage, changing the medication, adding new medications, or considering alternative treatments.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

Ifosfamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. Ifosfamide is used to treat various types of cancers, such as testicular cancer, small cell lung cancer, ovarian cancer, cervical cancer, and certain types of sarcomas.

The medical definition of Ifosfamide is:

Ifosfamide is a synthetic antineoplastic agent, an oxazaphosphorine derivative, with the chemical formula C6H15Cl2N2O2P. It is used in the treatment of various malignancies, including germ cell tumors, sarcomas, lymphomas, and testicular cancer. The drug is administered intravenously and exerts its cytotoxic effects through the alkylation and cross-linking of DNA, leading to the inhibition of DNA replication and transcription. Ifosfamide can cause significant myelosuppression and has been associated with urotoxicity, neurotoxicity, and secondary malignancies. Therefore, it is essential to monitor patients closely during treatment and manage any adverse effects promptly.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

Etoposide is a chemotherapy medication used to treat various types of cancer, including lung cancer, testicular cancer, and certain types of leukemia. It works by inhibiting the activity of an enzyme called topoisomerase II, which is involved in DNA replication and transcription. By doing so, etoposide can interfere with the growth and multiplication of cancer cells.

Etoposide is often administered intravenously in a hospital or clinic setting, although it may also be given orally in some cases. The medication can cause a range of side effects, including nausea, vomiting, hair loss, and an increased risk of infection. It can also have more serious side effects, such as bone marrow suppression, which can lead to anemia, bleeding, and a weakened immune system.

Like all chemotherapy drugs, etoposide is not without risks and should only be used under the close supervision of a qualified healthcare provider. It is important for patients to discuss the potential benefits and risks of this medication with their doctor before starting treatment.

Autologous transplantation is a medical procedure where cells, tissues, or organs are removed from a person, stored and then returned back to the same individual at a later time. This is different from allogeneic transplantation where the tissue or organ is obtained from another donor. The term "autologous" is derived from the Greek words "auto" meaning self and "logos" meaning study.

In autologous transplantation, the patient's own cells or tissues are used to replace or repair damaged or diseased ones. This reduces the risk of rejection and eliminates the need for immunosuppressive drugs, which are required in allogeneic transplants to prevent the body from attacking the foreign tissue.

Examples of autologous transplantation include:

* Autologous bone marrow or stem cell transplantation, where stem cells are removed from the patient's blood or bone marrow, stored and then reinfused back into the same individual after high-dose chemotherapy or radiation therapy to treat cancer.
* Autologous skin grafting, where a piece of skin is taken from one part of the body and transplanted to another area on the same person.
* Autologous chondrocyte implantation, where cartilage cells are harvested from the patient's own knee, cultured in a laboratory and then implanted back into the knee to repair damaged cartilage.

Local neoplasm recurrence is the return or regrowth of a tumor in the same location where it was originally removed or treated. This means that cancer cells have survived the initial treatment and started to grow again in the same area. It's essential to monitor and detect any local recurrence as early as possible, as it can affect the prognosis and may require additional treatment.

Cytarabine is a chemotherapeutic agent used in the treatment of various types of cancer, including leukemias and lymphomas. Its chemical name is cytosine arabinoside, and it works by interfering with the DNA synthesis of cancer cells, which ultimately leads to their death.

Cytarabine is often used in combination with other chemotherapy drugs and may be administered through various routes, such as intravenous (IV) or subcutaneous injection, or orally. The specific dosage and duration of treatment will depend on the type and stage of cancer being treated, as well as the patient's overall health status.

Like all chemotherapy drugs, cytarabine can cause a range of side effects, including nausea, vomiting, diarrhea, hair loss, and an increased risk of infection. It may also cause more serious side effects, such as damage to the liver, kidneys, or nervous system, and it is important for patients to be closely monitored during treatment to minimize these risks.

It's important to note that medical treatments should only be administered under the supervision of a qualified healthcare professional, and this information should not be used as a substitute for medical advice.

High-Intensity Focused Ultrasound (HIFU), Transrectal:

High-Intensity Focused Ultrasound (HIFU) is a non-invasive therapeutic technique that uses ultrasound waves to heat and destroy targeted tissue. In the transrectal approach, an ultrasound probe is inserted into the rectum to focus the ultrasound beams on a specific area, usually in the prostate gland. The high-intensity focused ultrasound energy raises the temperature of the targeted prostate tissue, leading to coagulative necrosis and ablation. This method is used to treat localized prostate cancer, offering an alternative to surgery or radiation therapy. It's important to note that HIFU transrectal treatment requires specialized equipment and training for its proper application.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Disease-free survival (DFS) is a term used in medical research and clinical practice, particularly in the field of oncology. It refers to the length of time after primary treatment for a cancer during which no evidence of the disease can be found. This means that the patient shows no signs or symptoms of the cancer, and any imaging studies or other tests do not reveal any tumors or other indications of the disease.

DFS is often used as an important endpoint in clinical trials to evaluate the effectiveness of different treatments for cancer. By measuring the length of time until the cancer recurs or a new cancer develops, researchers can get a better sense of how well a particular treatment is working and whether it is improving patient outcomes.

It's important to note that DFS is not the same as overall survival (OS), which refers to the length of time from primary treatment until death from any cause. While DFS can provide valuable information about the effectiveness of cancer treatments, it does not necessarily reflect the impact of those treatments on patients' overall survival.

A germinoma is a type of tumor that develops in the brain or the spine, primarily in the pituitary gland or pineal gland. It is a rare form of primary central nervous system (CNS) cancer and is classified as a type of germ cell tumor. These tumors arise from cells that normally develop into sperm or eggs, which can migrate to unusual locations during embryonic development.

Germinomas are highly sensitive to radiation therapy and chemotherapy, making them generally treatable and curable with appropriate medical intervention. Symptoms of a germinoma may include headaches, nausea, vomiting, visual disturbances, hormonal imbalances, and neurological deficits, depending on the location and size of the tumor. Diagnosis typically involves imaging studies like MRI or CT scans, followed by a biopsy to confirm the presence of malignant cells.

Thalidomide is a pharmaceutical drug that was initially developed and marketed as a sedative and treatment for morning sickness in pregnant women. However, it was later found to cause severe birth defects when given during pregnancy, particularly damage to the limbs, ears, and eyes of the developing fetus. As a result, thalidomide was banned in many countries in the 1960s.

In recent years, thalidomide has been reintroduced as a treatment for certain medical conditions, including multiple myeloma (a type of cancer that affects plasma cells) and leprosy. It is also being studied as a potential treatment for other diseases, such as rheumatoid arthritis and Crohn's disease.

Thalidomide works by suppressing the immune system and inhibiting the formation of new blood vessels (angiogenesis). However, its use is tightly regulated due to its teratogenic effects, meaning it can cause birth defects if taken during pregnancy. Women who are pregnant or planning to become pregnant should not take thalidomide, and healthcare providers must follow strict guidelines when prescribing the drug to ensure that it is used safely and effectively.

Medical survival rate is a statistical measure used to determine the percentage of patients who are still alive for a specific period of time after their diagnosis or treatment for a certain condition or disease. It is often expressed as a five-year survival rate, which refers to the proportion of people who are alive five years after their diagnosis. Survival rates can be affected by many factors, including the stage of the disease at diagnosis, the patient's age and overall health, the effectiveness of treatment, and other health conditions that the patient may have. It is important to note that survival rates are statistical estimates and do not necessarily predict an individual patient's prognosis.

Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the immune system. It involves the abnormal growth and proliferation of malignant lymphocytes (a type of white blood cell), leading to the formation of tumors in lymph nodes, spleen, bone marrow, or other organs. NHL can be further classified into various subtypes based on the specific type of lymphocyte involved and its characteristics.

The symptoms of Non-Hodgkin lymphoma may include:

* Painless swelling of lymph nodes in the neck, armpits, or groin
* Persistent fatigue
* Unexplained weight loss
* Fever
* Night sweats
* Itchy skin

The exact cause of Non-Hodgkin lymphoma is not well understood, but it has been associated with certain risk factors such as age (most common in people over 60), exposure to certain chemicals, immune system deficiencies, and infection with viruses like Epstein-Barr virus or HIV.

Treatment for Non-Hodgkin lymphoma depends on the stage and subtype of the disease, as well as the patient's overall health. Treatment options may include chemotherapy, radiation therapy, immunotherapy, targeted therapy, stem cell transplantation, or a combination of these approaches. Regular follow-up care is essential to monitor the progression of the disease and manage any potential long-term side effects of treatment.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

Hematopoietic Stem Cell Transplantation (HSCT) is a medical procedure where hematopoietic stem cells (immature cells that give rise to all blood cell types) are transplanted into a patient. This procedure is often used to treat various malignant and non-malignant disorders affecting the hematopoietic system, such as leukemias, lymphomas, multiple myeloma, aplastic anemia, inherited immune deficiency diseases, and certain genetic metabolic disorders.

The transplantation can be autologous (using the patient's own stem cells), allogeneic (using stem cells from a genetically matched donor, usually a sibling or unrelated volunteer), or syngeneic (using stem cells from an identical twin).

The process involves collecting hematopoietic stem cells, most commonly from the peripheral blood or bone marrow. The collected cells are then infused into the patient after the recipient's own hematopoietic system has been ablated (or destroyed) using high-dose chemotherapy and/or radiation therapy. This allows the donor's stem cells to engraft, reconstitute, and restore the patient's hematopoietic system.

HSCT is a complex and potentially risky procedure with various complications, including graft-versus-host disease, infections, and organ damage. However, it offers the potential for cure or long-term remission in many patients with otherwise fatal diseases.

Anticipatory vomiting is a condition characterized by the experience of nausea and vomiting in response to a stimulus that a person has learned to associate with previous episodes of emesis (vomiting). It is often observed in patients who have undergone chemotherapy or radiation therapy for cancer treatment. The sight, smell, taste, or even thought of the treatment setting can trigger the body's vomiting reflex, even before any medication is administered. This condition can be distressing and may negatively impact a patient's quality of life. Various interventions, such as behavioral therapies, relaxation techniques, and medications, can be used to manage anticipatory vomiting.

Monoclonal murine-derived antibodies are a type of laboratory-produced antibody that is identical in structure, having been derived from a single clone of cells. These antibodies are created using mouse cells and are therefore composed entirely of mouse immune proteins. They are designed to bind specifically to a particular target protein or antigen, making them useful tools for research, diagnostic testing, and therapeutic applications.

Monoclonal antibodies offer several advantages over polyclonal antibodies (which are derived from multiple clones of cells and can recognize multiple epitopes on an antigen). Monoclonal antibodies have a consistent and uniform structure, making them more reliable for research and diagnostic purposes. They also have higher specificity and affinity for their target antigens, allowing for more sensitive detection and measurement.

However, there are some limitations to using monoclonal murine-derived antibodies in therapeutic applications. Because they are composed entirely of mouse proteins, they can elicit an immune response in humans, leading to the production of human anti-mouse antibodies (HAMA) that can neutralize their effectiveness. To overcome this limitation, researchers have developed chimeric and humanized monoclonal antibodies that incorporate human protein sequences, reducing the risk of an immune response.

Prognosis is a medical term that refers to the prediction of the likely outcome or course of a disease, including the chances of recovery or recurrence, based on the patient's symptoms, medical history, physical examination, and diagnostic tests. It is an important aspect of clinical decision-making and patient communication, as it helps doctors and patients make informed decisions about treatment options, set realistic expectations, and plan for future care.

Prognosis can be expressed in various ways, such as percentages, categories (e.g., good, fair, poor), or survival rates, depending on the nature of the disease and the available evidence. However, it is important to note that prognosis is not an exact science and may vary depending on individual factors, such as age, overall health status, and response to treatment. Therefore, it should be used as a guide rather than a definitive forecast.

Carmustine is a chemotherapy drug used to treat various types of cancer, including brain tumors, multiple myeloma, and Hodgkin's lymphoma. It belongs to a class of drugs called alkylating agents, which work by damaging the DNA in cancer cells, preventing them from dividing and growing.

Carmustine is available as an injectable solution that is administered intravenously (into a vein) or as implantable wafers that are placed directly into the brain during surgery. The drug can cause side effects such as nausea, vomiting, hair loss, and low blood cell counts, among others. It may also increase the risk of certain infections and bleeding complications.

As with all chemotherapy drugs, carmustine can have serious and potentially life-threatening side effects, and it should only be administered under the close supervision of a qualified healthcare professional. Patients receiving carmustine treatment should be closely monitored for signs of toxicity and other adverse reactions.

Cisplatin is a chemotherapeutic agent used to treat various types of cancers, including testicular, ovarian, bladder, head and neck, lung, and cervical cancers. It is an inorganic platinum compound that contains a central platinum atom surrounded by two chloride atoms and two ammonia molecules in a cis configuration.

Cisplatin works by forming crosslinks between DNA strands, which disrupts the structure of DNA and prevents cancer cells from replicating. This ultimately leads to cell death and slows down or stops the growth of tumors. However, cisplatin can also cause damage to normal cells, leading to side effects such as nausea, vomiting, hearing loss, and kidney damage. Therefore, it is essential to monitor patients closely during treatment and manage any adverse effects promptly.

Vinblastine is an alkaloid derived from the Madagascar periwinkle plant (Catharanthus roseus) and is primarily used in cancer chemotherapy. It is classified as a vinca alkaloid, along with vincristine, vinorelbine, and others.

Medically, vinblastine is an antimicrotubule agent that binds to tubulin, a protein involved in the formation of microtubules during cell division. By binding to tubulin, vinblastine prevents the assembly of microtubules, which are essential for mitosis (cell division). This leads to the inhibition of cell division and ultimately results in the death of rapidly dividing cells, such as cancer cells.

Vinblastine is used to treat various types of cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, breast cancer, and others. It is often administered intravenously in a healthcare setting and may be given as part of a combination chemotherapy regimen with other anticancer drugs.

As with any medication, vinblastine can have side effects, including bone marrow suppression (leading to an increased risk of infection, anemia, and bleeding), neurotoxicity (resulting in peripheral neuropathy, constipation, and jaw pain), nausea, vomiting, hair loss, and mouth sores. Regular monitoring by a healthcare professional is necessary during vinblastine treatment to manage side effects and ensure the safe and effective use of this medication.

Aspergillosis is a medical condition that is caused by the infection of the Aspergillus fungi. This fungus is commonly found in decaying organic matter, such as leaf litter and compost piles, and can also be found in some indoor environments like air conditioning systems and old buildings with water damage.

There are several types of aspergillosis, including:

1. Allergic bronchopulmonary aspergillosis (ABPA): This type of aspergillosis occurs when a person's immune system overreacts to the Aspergillus fungi, causing inflammation in the airways and lungs. ABPA is often seen in people with asthma or cystic fibrosis.
2. Invasive aspergillosis: This is a serious and potentially life-threatening condition that occurs when the Aspergillus fungi invade the bloodstream and spread to other organs, such as the brain, heart, or kidneys. Invasive aspergillosis typically affects people with weakened immune systems, such as those undergoing chemotherapy or organ transplantation.
3. Aspergilloma: Also known as a "fungus ball," an aspergilloma is a growth of the Aspergillus fungi that forms in a preexisting lung cavity, such as one caused by previous lung disease or injury. While an aspergilloma itself is not typically harmful, it can cause symptoms like coughing up blood or chest pain if it grows too large or becomes infected.

Symptoms of aspergillosis can vary depending on the type and severity of the infection. Treatment may include antifungal medications, surgery to remove the fungal growth, or management of underlying conditions that increase the risk of infection.

Multiple myeloma is a type of cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help your body fight infection by producing antibodies. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than producing useful antibodies, the cancer cells produce abnormal proteins that can cause complications such as kidney damage, bone pain and fractures.

Multiple myeloma is a type of cancer called a plasma cell neoplasm. Plasma cell neoplasms are diseases in which there is an overproduction of a single clone of plasma cells. In multiple myeloma, this results in the crowding out of normal plasma cells, red and white blood cells and platelets, leading to many of the complications associated with the disease.

The abnormal proteins produced by the cancer cells can also cause damage to organs and tissues in the body. These abnormal proteins can be detected in the blood or urine and are often used to monitor the progression of multiple myeloma.

Multiple myeloma is a relatively uncommon cancer, but it is the second most common blood cancer after non-Hodgkin lymphoma. It typically occurs in people over the age of 65, and men are more likely to develop multiple myeloma than women. While there is no cure for multiple myeloma, treatments such as chemotherapy, radiation therapy, and stem cell transplantation can help manage the disease and its symptoms, and improve quality of life.

A "Drug Administration Schedule" refers to the plan for when and how a medication should be given to a patient. It includes details such as the dose, frequency (how often it should be taken), route (how it should be administered, such as orally, intravenously, etc.), and duration (how long it should be taken) of the medication. This schedule is often created and prescribed by healthcare professionals, such as doctors or pharmacists, to ensure that the medication is taken safely and effectively. It may also include instructions for missed doses or changes in the dosage.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Cyclophosphamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. This helps to stop the spread of cancer in the body. Cyclophosphamide is used to treat various types of cancer, including lymphoma, leukemia, multiple myeloma, and breast cancer. It can be given orally as a tablet or intravenously as an injection.

Cyclophosphamide can also have immunosuppressive effects, which means it can suppress the activity of the immune system. This makes it useful in treating certain autoimmune diseases, such as rheumatoid arthritis and lupus. However, this immunosuppression can also increase the risk of infections and other side effects.

Like all chemotherapy medications, cyclophosphamide can cause a range of side effects, including nausea, vomiting, hair loss, fatigue, and increased susceptibility to infections. It is important for patients receiving cyclophosphamide to be closely monitored by their healthcare team to manage these side effects and ensure the medication is working effectively.

Glossectomy is a surgical procedure that involves the partial or total removal of the tongue. This type of surgery may be performed for various reasons, such as treating certain types of cancer (like oral or tongue cancer) that have not responded to other forms of treatment, or removing a portion of the tongue that's severely damaged or injured due to trauma.

The extent of the glossectomy depends on the size and location of the tumor or lesion. A partial glossectomy refers to the removal of a part of the tongue, while a total glossectomy involves the complete excision of the tongue. In some cases, reconstructive surgery may be performed to help restore speech and swallowing functions after the procedure.

It is essential to note that a glossectomy can significantly impact a patient's quality of life, as the tongue plays crucial roles in speaking, swallowing, and taste sensation. Therefore, multidisciplinary care involving speech therapists, dietitians, and other healthcare professionals is often necessary to help patients adapt to their new conditions and optimize their recovery process.

Stem cell transplantation is a medical procedure where stem cells, which are immature and unspecialized cells with the ability to differentiate into various specialized cell types, are introduced into a patient. The main purpose of this procedure is to restore the function of damaged or destroyed tissues or organs, particularly in conditions that affect the blood and immune systems, such as leukemia, lymphoma, aplastic anemia, and inherited metabolic disorders.

There are two primary types of stem cell transplantation: autologous and allogeneic. In autologous transplantation, the patient's own stem cells are collected, stored, and then reinfused back into their body after high-dose chemotherapy or radiation therapy to destroy the diseased cells. In allogeneic transplantation, stem cells are obtained from a donor (related or unrelated) whose human leukocyte antigen (HLA) type closely matches that of the recipient.

The process involves several steps: first, the patient undergoes conditioning therapy to suppress their immune system and make space for the new stem cells. Then, the harvested stem cells are infused into the patient's bloodstream, where they migrate to the bone marrow and begin to differentiate and produce new blood cells. This procedure requires close monitoring and supportive care to manage potential complications such as infections, graft-versus-host disease, and organ damage.

Operative blood salvage, also known as intraoperative blood recovery or cell salvage, is a medical procedure that involves the collection, washing, and reinfusion of a patient's own blood during surgery. The blood is collected from the surgical site using a suction device and then processed to remove any debris, clots, and free hemoglobin. The resulting red blood cells are then washed and suspended in a sterile solution before being returned to the patient through a transfusion.

This technique is commonly used during surgeries where significant blood loss is expected, such as orthopedic, cardiovascular, and major cancer surgeries. It offers several advantages over allogeneic (donor) blood transfusions, including reduced exposure to potential transfusion reactions, decreased risk of infectious disease transmission, and lower costs. However, it may not be appropriate for all patients or surgical procedures, and its use should be carefully considered based on the individual patient's medical history and condition.

Dexamethasone is a type of corticosteroid medication, which is a synthetic version of a natural hormone produced by the adrenal glands. It is often used to reduce inflammation and suppress the immune system in a variety of medical conditions, including allergies, asthma, rheumatoid arthritis, and certain skin conditions.

Dexamethasone works by binding to specific receptors in cells, which triggers a range of anti-inflammatory effects. These include reducing the production of chemicals that cause inflammation, suppressing the activity of immune cells, and stabilizing cell membranes.

In addition to its anti-inflammatory effects, dexamethasone can also be used to treat other medical conditions, such as certain types of cancer, brain swelling, and adrenal insufficiency. It is available in a variety of forms, including tablets, liquids, creams, and injectable solutions.

Like all medications, dexamethasone can have side effects, particularly if used for long periods of time or at high doses. These may include mood changes, increased appetite, weight gain, acne, thinning skin, easy bruising, and an increased risk of infections. It is important to follow the instructions of a healthcare provider when taking dexamethasone to minimize the risk of side effects.

Melphalan is an antineoplastic agent, specifically an alkylating agent. It is used in the treatment of multiple myeloma and other types of cancer. The medical definition of Melphalan is:

A nitrogen mustard derivative that is used as an alkylating agent in the treatment of cancer, particularly multiple myeloma and ovarian cancer. Melphalan works by forming covalent bonds with DNA, resulting in cross-linking of the double helix and inhibition of DNA replication and transcription. This ultimately leads to cell cycle arrest and apoptosis (programmed cell death) in rapidly dividing cells, such as cancer cells.

Melphalan is administered orally or intravenously, and its use is often accompanied by other anticancer therapies, such as radiation therapy or chemotherapy. Common side effects of Melphalan include nausea, vomiting, diarrhea, and bone marrow suppression, which can lead to anemia, neutropenia, and thrombocytopenia. Other potential side effects include hair loss, mucositis, and secondary malignancies.

It is important to note that Melphalan should be used under the close supervision of a healthcare professional, as it can cause serious adverse reactions if not administered correctly.

Drug resistance, viral, refers to the ability of a virus to continue replicating in the presence of antiviral drugs that are designed to inhibit or stop its growth. This occurs when the virus mutates and changes its genetic makeup in such a way that the drug can no longer effectively bind to and inhibit the function of its target protein, allowing the virus to continue infecting host cells and causing disease.

Viral drug resistance can develop due to several factors, including:

1. Mutations in the viral genome that alter the structure or function of the drug's target protein.
2. Changes in the expression levels or location of the drug's target protein within the virus-infected cell.
3. Activation of alternative pathways that allow the virus to replicate despite the presence of the drug.
4. Increased efflux of the drug from the virus-infected cell, reducing its intracellular concentration and effectiveness.

Viral drug resistance is a significant concern in the treatment of viral infections such as HIV, hepatitis B and C, herpes simplex virus, and influenza. It can lead to reduced treatment efficacy, increased risk of treatment failure, and the need for more toxic or expensive drugs. Therefore, it is essential to monitor viral drug resistance during treatment and adjust therapy accordingly to ensure optimal outcomes.

Podophyllotoxin is a pharmaceutical agent derived from the podophyllum plant. It is an antimitotic compound that inhibits microtubule assembly, leading to cell cycle arrest and apoptosis. It is primarily used in topical form as a treatment for genital warts, caused by certain types of human papillomavirus (HPV). Podophyllotoxin works by interfering with the growth of the wart cells, eventually causing them to die off.

It's important to note that podophyllotoxin is a potent cytotoxic agent and should only be used under the supervision of a healthcare professional. It should not be taken orally or applied to open wounds, and it should be kept out of reach of children.

Zygomycosis is a rare, but serious fungal infection caused by filamentous fungi of the class Zygomycetes. These fungi are commonly found in the environment, particularly in soil and decaying organic matter. The infection primarily affects individuals with weakened immune systems, such as those with uncontrolled diabetes, HIV/AIDS, or those receiving immunosuppressive therapy.

Zygomycosis can manifest in various forms depending on the site of infection. The two main types are rhinocerebral zygomycosis (affecting the sinuses and brain) and pulmonary zygomycosis (affecting the lungs). Other forms include cutaneous (skin), gastrointestinal, and disseminated zygomycosis. Symptoms can range from mild to severe and may include fever, cough, shortness of breath, sinus pain or congestion, skin lesions, and neurological symptoms like headache, altered mental status, or vision changes.

Early diagnosis and prompt treatment with antifungal medications and surgical debridement are crucial for managing zygomycosis. The prognosis depends on the patient's underlying health condition and the extent of infection at the time of diagnosis.

Prednimustine is not a standalone medication, but rather a combination of two active ingredients: prednisone, a corticosteroid, and chlorambucil, an alkylating agent used in chemotherapy. Prednimustine is a sterile lyophilized powder that is reconstituted with sterile water for injection before use. It is primarily used in the treatment of various types of cancer, including Hodgkin's lymphoma and non-Hodgkin's lymphoma.

The combination of prednisone and chlorambucil in Prednimustine provides a synergistic effect in suppressing the immune system and damaging the DNA of cancer cells, which can lead to cell death and reduced tumor growth. The corticosteroid component, prednisone, helps to reduce inflammation and suppress the immune response, while chlorambucil directly damages the DNA of cancer cells, leading to their destruction.

It is important to note that Prednimustine should only be administered under the supervision of a qualified healthcare professional, as it can have serious side effects, including bone marrow suppression, gastrointestinal disturbances, and increased risk of infections.

Bone marrow transplantation (BMT) is a medical procedure in which damaged or destroyed bone marrow is replaced with healthy bone marrow from a donor. Bone marrow is the spongy tissue inside bones that produces blood cells. The main types of BMT are autologous, allogeneic, and umbilical cord blood transplantation.

In autologous BMT, the patient's own bone marrow is used for the transplant. This type of BMT is often used in patients with lymphoma or multiple myeloma who have undergone high-dose chemotherapy or radiation therapy to destroy their cancerous bone marrow.

In allogeneic BMT, bone marrow from a genetically matched donor is used for the transplant. This type of BMT is often used in patients with leukemia, lymphoma, or other blood disorders who have failed other treatments.

Umbilical cord blood transplantation involves using stem cells from umbilical cord blood as a source of healthy bone marrow. This type of BMT is often used in children and adults who do not have a matched donor for allogeneic BMT.

The process of BMT typically involves several steps, including harvesting the bone marrow or stem cells from the donor, conditioning the patient's body to receive the new bone marrow or stem cells, transplanting the new bone marrow or stem cells into the patient's body, and monitoring the patient for signs of engraftment and complications.

BMT is a complex and potentially risky procedure that requires careful planning, preparation, and follow-up care. However, it can be a life-saving treatment for many patients with blood disorders or cancer.

Testicular neoplasms are abnormal growths or tumors in the testicle that can be benign (non-cancerous) or malignant (cancerous). They are a type of genitourinary cancer, which affects the reproductive and urinary systems. Testicular neoplasms can occur in men of any age but are most commonly found in young adults between the ages of 15 and 40.

Testicular neoplasms can be classified into two main categories: germ cell tumors and non-germ cell tumors. Germ cell tumors, which arise from the cells that give rise to sperm, are further divided into seminomas and non-seminomas. Seminomas are typically slow-growing and have a good prognosis, while non-seminomas tend to grow more quickly and can spread to other parts of the body.

Non-germ cell tumors are less common than germ cell tumors and include Leydig cell tumors, Sertoli cell tumors, and lymphomas. These tumors can have a variety of clinical behaviors, ranging from benign to malignant.

Testicular neoplasms often present as a painless mass or swelling in the testicle. Other symptoms may include a feeling of heaviness or discomfort in the scrotum, a dull ache in the lower abdomen or groin, and breast enlargement (gynecomastia).

Diagnosis typically involves a physical examination, imaging studies such as ultrasound or CT scan, and blood tests to detect tumor markers. Treatment options depend on the type and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular self-examinations of the testicles are recommended for early detection and improved outcomes.

Antifungal agents are a type of medication used to treat and prevent fungal infections. These agents work by targeting and disrupting the growth of fungi, which include yeasts, molds, and other types of fungi that can cause illness in humans.

There are several different classes of antifungal agents, including:

1. Azoles: These agents work by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes. Examples of azole antifungals include fluconazole, itraconazole, and voriconazole.
2. Echinocandins: These agents target the fungal cell wall, disrupting its synthesis and leading to fungal cell death. Examples of echinocandins include caspofungin, micafungin, and anidulafungin.
3. Polyenes: These agents bind to ergosterol in the fungal cell membrane, creating pores that lead to fungal cell death. Examples of polyene antifungals include amphotericin B and nystatin.
4. Allylamines: These agents inhibit squalene epoxidase, a key enzyme in ergosterol synthesis. Examples of allylamine antifungals include terbinafine and naftifine.
5. Griseofulvin: This agent disrupts fungal cell division by binding to tubulin, a protein involved in fungal cell mitosis.

Antifungal agents can be administered topically, orally, or intravenously, depending on the severity and location of the infection. It is important to use antifungal agents only as directed by a healthcare professional, as misuse or overuse can lead to resistance and make treatment more difficult.

Idarubicin is an anthracycline antibiotic used in the treatment of various types of cancer, including leukemia and lymphoma. It works by interfering with the DNA of cancer cells, which prevents them from dividing and growing. Idarubicin is often administered intravenously in a hospital or clinic setting. Common side effects include nausea, vomiting, hair loss, and an increased risk of infection due to lowered white blood cell counts. It can also cause damage to the heart muscle, so regular monitoring of cardiac function is necessary during treatment.

Bleomycin is a type of chemotherapeutic agent used to treat various types of cancer, including squamous cell carcinoma, testicular cancer, and lymphomas. It works by causing DNA damage in rapidly dividing cells, which can inhibit the growth and proliferation of cancer cells.

Bleomycin is an antibiotic derived from Streptomyces verticillus and is often administered intravenously or intramuscularly. While it can be effective in treating certain types of cancer, it can also have serious side effects, including lung toxicity, which can lead to pulmonary fibrosis and respiratory failure. Therefore, bleomycin should only be used under the close supervision of a healthcare professional who is experienced in administering chemotherapy drugs.

Multiple drug resistance (MDR) in viruses refers to the ability of a virus to resist or inhibit the effects of multiple antiviral agents. This occurs when a virus mutates and develops mechanisms that prevent antiviral drugs from effectively binding to their target sites, rendering the drugs unable to suppress viral replication.

In the context of virology, "multiple" typically means resistance to at least three or more classes of antiviral drugs. This is a significant concern in the management of viral infections such as HIV, HCV, and influenza, where MDR can lead to reduced treatment options, increased risk of disease progression, and potential transmission of resistant strains. Regular monitoring and appropriate use of antiviral agents are crucial for preventing and managing multiple drug resistance in viruses.

Mechlorethamine is an antineoplastic agent, which means it is used to treat cancer. It is a type of alkylating agent, which is a class of drugs that work by interfering with the DNA of cancer cells, preventing them from dividing and growing. Mechlorethamine is used in the treatment of Hodgkin's lymphoma and non-Hodgkin's lymphoma, as well as some other types of cancer. It can be administered intravenously or topically (as a cream) to treat skin lesions caused by certain types of cancer.

Mechlorethamine is a potent drug that can have significant side effects, including nausea, vomiting, hair loss, and an increased risk of infection due to suppression of the immune system. It can also cause damage to the heart, lungs, and reproductive system with long-term use. As with all chemotherapy drugs, mechlorethamine should be administered under the close supervision of a healthcare professional.

Doxorubicin is a type of chemotherapy medication known as an anthracycline. It works by interfering with the DNA in cancer cells, which prevents them from growing and multiplying. Doxorubicin is used to treat a wide variety of cancers, including leukemia, lymphoma, breast cancer, lung cancer, ovarian cancer, and many others. It may be given alone or in combination with other chemotherapy drugs.

Doxorubicin is usually administered through a vein (intravenously) and can cause side effects such as nausea, vomiting, hair loss, mouth sores, and increased risk of infection. It can also cause damage to the heart muscle, which can lead to heart failure in some cases. For this reason, doctors may monitor patients' heart function closely while they are receiving doxorubicin treatment.

It is important for patients to discuss the potential risks and benefits of doxorubicin therapy with their healthcare provider before starting treatment.

Homologous transplantation is a type of transplant surgery where organs or tissues are transferred between two genetically non-identical individuals of the same species. The term "homologous" refers to the similarity in structure and function of the donated organ or tissue to the recipient's own organ or tissue.

For example, a heart transplant from one human to another is an example of homologous transplantation because both organs are hearts and perform the same function. Similarly, a liver transplant, kidney transplant, lung transplant, and other types of organ transplants between individuals of the same species are also considered homologous transplantations.

Homologous transplantation is in contrast to heterologous or xenogeneic transplantation, where organs or tissues are transferred from one species to another, such as a pig heart transplanted into a human. Homologous transplantation is more commonly performed than heterologous transplantation due to the increased risk of rejection and other complications associated with xenogeneic transplants.

Prednisone is a synthetic glucocorticoid, which is a type of corticosteroid hormone. It is primarily used to reduce inflammation in various conditions such as asthma, allergies, arthritis, and autoimmune disorders. Prednisone works by mimicking the effects of natural hormones produced by the adrenal glands, suppressing the immune system's response and reducing the release of substances that cause inflammation.

It is available in oral tablet form and is typically prescribed to be taken at specific times during the day, depending on the condition being treated. Common side effects of prednisone include increased appetite, weight gain, mood changes, insomnia, and easy bruising. Long-term use or high doses can lead to more serious side effects such as osteoporosis, diabetes, cataracts, and increased susceptibility to infections.

Healthcare providers closely monitor patients taking prednisone for extended periods to minimize the risk of adverse effects. It is essential to follow the prescribed dosage regimen and not discontinue the medication abruptly without medical supervision, as this can lead to withdrawal symptoms or a rebound of the underlying condition.

Vincristine is an antineoplastic agent, specifically a vinca alkaloid. It is derived from the Madagascar periwinkle plant (Catharanthus roseus). Vincristine binds to tubulin, a protein found in microtubules, and inhibits their polymerization, which results in disruption of mitotic spindles leading to cell cycle arrest and apoptosis (programmed cell death). It is used in the treatment of various types of cancer including leukemias, lymphomas, and solid tumors. Common side effects include peripheral neuropathy, constipation, and alopecia.

Vidarabine is an antiviral medication used to treat herpes simplex infections, particularly severe cases such as herpes encephalitis (inflammation of the brain caused by the herpes simplex virus). It works by interfering with the DNA replication of the virus.

In medical terms, vidarabine is a nucleoside analogue that is phosphorylated intracellularly to the active form, vidarabine triphosphate. This compound inhibits viral DNA polymerase and incorporates into viral DNA, causing termination of viral DNA synthesis.

Vidarabine was previously used as an injectable medication but has largely been replaced by more modern antiviral drugs such as acyclovir due to its greater efficacy and lower toxicity.

Amputation is defined as the surgical removal of all or part of a limb or extremity such as an arm, leg, foot, hand, toe, or finger. This procedure is typically performed to remove damaged or dead tissue due to various reasons like severe injury, infection, tumors, or chronic conditions that impair circulation, such as diabetes or peripheral arterial disease. The goal of amputation is to alleviate pain, prevent further complications, and improve the patient's quality of life. Following the surgery, patients may require rehabilitation and prosthetic devices to help them adapt to their new physical condition.

A prostatectomy is a surgical procedure where all or part of the prostate gland is removed. This surgery can be performed through various approaches such as open surgery, laparoscopic surgery, or robotic-assisted surgery. The type of prostatectomy performed depends on the reason for the surgery and the patient's individual circumstances.

There are two main types of prostatectomies: radical and simple. A radical prostatectomy is a surgical procedure to remove the entire prostate gland, seminal vesicles, and surrounding lymph nodes. This type of prostatectomy is typically performed as a treatment for prostate cancer.

A simple prostatectomy, on the other hand, involves removing only the inner part of the prostate gland that is causing symptoms such as difficulty urinating or bladder obstruction. Simple prostatectomies are usually performed to alleviate benign prostatic hyperplasia (BPH), which is a non-cancerous enlargement of the prostate gland.

Regardless of the type of prostatectomy, potential risks and complications include bleeding, infection, urinary incontinence, erectile dysfunction, and changes in sexual function. It is important for patients to discuss these risks with their healthcare provider before undergoing surgery.

Echinocandins are a class of antifungal medications that inhibit the synthesis of 1,3-β-D-glucan, a key component of the fungal cell wall. This results in osmotic instability and ultimately leads to fungal cell death. Echinocandins are commonly used to treat invasive fungal infections caused by Candida species and Aspergillus species. The three drugs in this class that are approved for use in humans are caspofungin, micafungin, and anidulafungin.

Here's a brief overview of each drug:

1. Caspofungin (Cancidas, Cancidas-W): This is the first echinocandin to be approved for use in humans. It is indicated for the treatment of invasive candidiasis, including candidemia, acute disseminated candidiasis, and other forms of Candida infections. Caspofungin is also approved for the prevention of Candida infections in patients undergoing hematopoietic stem cell transplantation.
2. Micafungin (Mycamine): This echinocandin is approved for the treatment of candidemia, esophageal candidiasis, and other forms of Candida infections. It is also used for the prevention of Candida infections in patients undergoing hematopoietic stem cell transplantation.
3. Anidulafungin (Eraxis): This echinocandin is approved for the treatment of esophageal candidiasis and candidemia, as well as other forms of Candida infections. It is also used for the prevention of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Echinocandins have a broad spectrum of activity against many fungal species, including those that are resistant to other classes of antifungal medications. They are generally well-tolerated and have a low incidence of drug interactions. However, they should be used with caution in patients with hepatic impairment, as their metabolism may be affected by liver dysfunction.

Triazoles are a class of antifungal medications that have broad-spectrum activity against various fungi, including yeasts, molds, and dermatophytes. They work by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, leading to increased permeability and disruption of fungal growth. Triazoles are commonly used in both systemic and topical formulations for the treatment of various fungal infections, such as candidiasis, aspergillosis, cryptococcosis, and dermatophytoses. Some examples of triazole antifungals include fluconazole, itraconazole, voriconazole, and posaconazole.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Prostate-Specific Antigen (PSA) is a glycoprotein enzyme produced by the epithelial cells of the prostate gland. It is primarily involved in liquefying semen after ejaculation, allowing sperm mobility.

In clinical medicine, PSA is used as a tumor marker, mainly for monitoring the treatment and recurrence of prostate cancer. Elevated levels of PSA can indicate inflammation, infection, benign prostatic hyperplasia (BPH), or prostate cancer. However, it's important to note that an elevated PSA level does not necessarily confirm cancer; further diagnostic tests like digital rectal examination, transrectal ultrasound, and prostate biopsy are often required for definitive diagnosis.

Doctors may also use PSA isoforms or derivatives, such as free PSA, total PSA, and PSA density, to help improve the specificity of cancer detection and differentiate between malignant and benign conditions.

HIV Protease Inhibitors are a class of antiretroviral medications used in the treatment of HIV infection. They work by blocking the activity of the HIV protease enzyme, which is necessary for the virus to replicate and infect new cells. By inhibiting this enzyme, the medication prevents the virus from maturing and assembling into new infectious particles.

HIV protease inhibitors are often used in combination with other antiretroviral drugs as part of a highly active antiretroviral therapy (HAART) regimen. This approach has been shown to effectively suppress viral replication, reduce the amount of virus in the bloodstream (viral load), and improve the health and longevity of people living with HIV.

Examples of HIV protease inhibitors include saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, atazanavir, darunavir, and tipranavir. These medications are usually taken orally in the form of tablets or capsules, and may be prescribed alone or in combination with other antiretroviral drugs.

It is important to note that HIV protease inhibitors can have significant side effects, including gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain, as well as metabolic changes such as increased cholesterol and triglyceride levels. Therefore, regular monitoring of liver function, lipid levels, and other health parameters is necessary to ensure safe and effective use of these medications.

Actuarial analysis is a process used in the field of actuarial science to evaluate and manage risk, typically for financial or insurance purposes. It involves the use of statistical modeling, mathematical calculations, and data analysis to estimate the probability and potential financial impact of various events or outcomes.

In a medical context, actuarial analysis may be used to assess the risks and costs associated with different health conditions, treatments, or patient populations. For example, an actuary might use data on morbidity rates, mortality rates, and healthcare utilization patterns to estimate the expected costs of providing coverage to a group of patients with a particular medical condition.

Actuarial analysis can help healthcare organizations, insurers, and policymakers make informed decisions about resource allocation, pricing, and risk management. It can also be used to develop predictive models that identify high-risk populations or forecast future trends in healthcare utilization and costs.

Drug resistance in neoplasms (also known as cancer drug resistance) refers to the ability of cancer cells to withstand the effects of chemotherapeutic agents or medications designed to kill or inhibit the growth of cancer cells. This can occur due to various mechanisms, including changes in the cancer cell's genetic makeup, alterations in drug targets, increased activity of drug efflux pumps, and activation of survival pathways.

Drug resistance can be intrinsic (present at the beginning of treatment) or acquired (developed during the course of treatment). It is a significant challenge in cancer therapy as it often leads to reduced treatment effectiveness, disease progression, and poor patient outcomes. Strategies to overcome drug resistance include the use of combination therapies, development of new drugs that target different mechanisms, and personalized medicine approaches that consider individual patient and tumor characteristics.

Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.

In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:

1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.

Examples of combination drug therapy include:

1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.

When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.

Mitoxantrone is a synthetic antineoplastic anthracenedione drug, which means it is used to treat cancer. Its medical definition can be found in various authoritative sources such as the Merck Manual or Stedman's Medical Dictionary. Here's a brief version of the definition from MedlinePlus, a service of the US National Library of Medicine:

"Mitoxantrone is used to treat certain types of cancer (e.g., breast cancer, leukemia, non-Hodgkin's lymphoma). It works by slowing or stopping the growth of cancer cells. Mitoxantrone belongs to a class of drugs known as antitumor antibiotics."

Please note that this is a simplified definition meant for general information purposes and does not include all the details that might be present in a comprehensive medical definition. Always consult a healthcare professional or refer to authoritative resources for accurate, detailed, and up-to-date information.

Large B-cell lymphoma, diffuse is a type of cancer that starts in cells called B-lymphocytes, which are part of the body's immune system. "Large B-cell" refers to the size and appearance of the abnormal cells when viewed under a microscope. "Diffuse" means that the abnormal cells are spread throughout the lymph node or tissue where the cancer has started, rather than being clustered in one area.

This type of lymphoma is typically aggressive, which means it grows and spreads quickly. It can occur almost anywhere in the body, but most commonly affects the lymph nodes, spleen, and bone marrow. Symptoms may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

Treatment for large B-cell lymphoma, diffuse typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, stem cell transplantation or targeted therapy may also be recommended. The prognosis varies depending on several factors, including the stage and location of the cancer, as well as the patient's age and overall health.

Anti-HIV agents are a class of medications specifically designed to treat HIV (Human Immunodeficiency Virus) infection. These drugs work by interfering with various stages of the HIV replication cycle, preventing the virus from infecting and killing CD4+ T cells, which are crucial for maintaining a healthy immune system.

There are several classes of anti-HIV agents, including:

1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs): These drugs act as faulty building blocks that the virus incorporates into its genetic material, causing the replication process to halt. Examples include zidovudine (AZT), lamivudine (3TC), and tenofovir.
2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs): These medications bind directly to the reverse transcriptase enzyme, altering its shape and preventing it from functioning properly. Examples include efavirenz, nevirapine, and rilpivirine.
3. Protease Inhibitors (PIs): These drugs target the protease enzyme, which is responsible for cleaving viral polyproteins into functional components. By inhibiting this enzyme, PIs prevent the formation of mature, infectious virus particles. Examples include atazanavir, darunavir, and lopinavir.
4. Integrase Strand Transfer Inhibitors (INSTIs): These medications block the integrase enzyme, which is responsible for inserting the viral genetic material into the host cell's DNA. By inhibiting this step, INSTIs prevent the virus from establishing a permanent infection within the host cell. Examples include raltegravir, dolutegravir, and bictegravir.
5. Fusion/Entry Inhibitors: These drugs target different steps of the viral entry process, preventing HIV from infecting CD4+ T cells. Examples include enfuvirtide (T-20), maraviroc, and ibalizumab.
6. Post-Attachment Inhibitors: This class of medications prevents the virus from attaching to the host cell's receptors, thereby inhibiting infection. Currently, there is only one approved post-attachment inhibitor, fostemsavir.

Combination therapy using multiple classes of antiretroviral drugs has been shown to effectively suppress viral replication and improve clinical outcomes in people living with HIV. Regular adherence to the prescribed treatment regimen is crucial for maintaining an undetectable viral load and reducing the risk of transmission.

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

Transplantation conditioning, also known as preparative regimen or immunoablative therapy, refers to the use of various treatments prior to transplantation of cells, tissues or organs. The main goal of transplantation conditioning is to suppress the recipient's immune system, allowing for successful engraftment and minimizing the risk of rejection of the donor tissue.

There are two primary types of transplantation conditioning: myeloablative and non-myeloablative.

1. Myeloablative conditioning is a more intensive regimen that involves the use of high-dose chemotherapy, radiation therapy or both. This approach eliminates not only immune cells but also stem cells in the bone marrow, requiring the recipient to receive a hematopoietic cell transplant (HCT) from the donor to reconstitute their blood and immune system.
2. Non-myeloablative conditioning is a less intensive regimen that primarily targets immune cells while sparing the stem cells in the bone marrow. This approach allows for mixed chimerism, where both recipient and donor immune cells coexist, reducing the risk of severe complications associated with myeloablative conditioning.

The choice between these two types of transplantation conditioning depends on various factors, including the type of transplant, patient's age, overall health, and comorbidities. Both approaches carry risks and benefits, and the decision should be made carefully by a multidisciplinary team of healthcare professionals in consultation with the patient.

Neoplasms, germ cell and embryonal are types of tumors that originate from the abnormal growth of cells. Here's a brief medical definition for each:

1. Neoplasms: Neoplasms refer to abnormal tissue growths or masses, which can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled cell division and may invade surrounding tissues or spread to other parts of the body through a process called metastasis.
2. Germ Cell Tumors: These are rare tumors that develop from the germ cells, which give rise to sperm and eggs in the reproductive organs (ovaries and testes). They can be benign or malignant and may occur in both children and adults. Germ cell tumors can also arise outside of the reproductive organs, a condition known as extragonadal germ cell tumors.
3. Embryonal Tumors: These are a type of malignant neoplasm that primarily affects infants and young children. They develop from embryonic cells, which are immature cells present during fetal development. Embryonal tumors can occur in various organs, including the brain (medulloblastomas), nervous system (primitive neuroectodermal tumors or PNETs), and other areas like the kidneys and liver.

It is essential to note that these conditions require professional medical evaluation and treatment by healthcare professionals with expertise in oncology and related fields.

Pyrimidinones are a class of heterocyclic organic compounds that contain a pyrimidine ring fused with a ketone group. The basic structure of a pyrimidinone consists of two nitrogen atoms and four carbon atoms in a six-membered ring, with a carbonyl (C=O) group attached to one of the carbon atoms.

In a medical context, pyrimidinones are important because many naturally occurring and synthetic compounds that contain this structure have been found to have biological activity. For example, some pyrimidinones have antiviral, antibacterial, or anticancer properties, making them useful in the development of new drugs for various medical conditions.

One well-known drug that contains a pyrimidinone ring is the antiviral medication Ribavirin, which is used to treat hepatitis C and certain viral hemorrhagic fevers. Other pyrimidinones are being studied for their potential therapeutic benefits in areas such as cancer therapy, neuroprotection, and inflammation.

Ischemia is the medical term used to describe a lack of blood flow to a part of the body, often due to blocked or narrowed blood vessels. This can lead to a shortage of oxygen and nutrients in the tissues, which can cause them to become damaged or die. Ischemia can affect many different parts of the body, including the heart, brain, legs, and intestines. Symptoms of ischemia depend on the location and severity of the blockage, but they may include pain, cramping, numbness, weakness, or coldness in the affected area. In severe cases, ischemia can lead to tissue death (gangrene) or organ failure. Treatment for ischemia typically involves addressing the underlying cause of the blocked blood flow, such as through medication, surgery, or lifestyle changes.

Boronic acids are organic compounds that contain a boron atom bonded to two carbon atoms and a hydroxyl group. The general formula for a boronic acid is RB(OH)2, where R represents a organic group. Boronic acids are important reagents in organic synthesis and have been used in the preparation of pharmaceuticals, agrochemicals, and materials science. They can also form stable complexes with many diols and phenols, which is the basis for their use in the detection and quantification of sugars, as well as in the design of boronic acid-based drugs that target diseases such as cancer and diabetes.

Precursor Cell Lymphoblastic Leukemia-Lymphoma (previously known as Precursor T-lymphoblastic Leukemia/Lymphoma) is a type of cancer that affects the early stages of T-cell development. It is a subtype of acute lymphoblastic leukemia (ALL), which is characterized by the overproduction of immature white blood cells called lymphoblasts in the bone marrow, blood, and other organs.

In Precursor Cell Lymphoblastic Leukemia-Lymphoma, these abnormal lymphoblasts accumulate primarily in the lymphoid tissues such as the thymus and lymph nodes, leading to the enlargement of these organs. This subtype is more aggressive than other forms of ALL and has a higher risk of spreading to the central nervous system (CNS).

The medical definition of Precursor Cell Lymphoblastic Leukemia-Lymphoma includes:

1. A malignant neoplasm of immature T-cell precursors, also known as lymphoblasts.
2. Characterized by the proliferation and accumulation of these abnormal cells in the bone marrow, blood, and lymphoid tissues such as the thymus and lymph nodes.
3. Often associated with chromosomal abnormalities, genetic mutations, or aberrant gene expression that contribute to its aggressive behavior and poor prognosis.
4. Typically presents with symptoms related to bone marrow failure (anemia, neutropenia, thrombocytopenia), lymphadenopathy (swollen lymph nodes), hepatosplenomegaly (enlarged liver and spleen), and potential CNS involvement.
5. Diagnosed through a combination of clinical evaluation, imaging studies, and laboratory tests, including bone marrow aspiration and biopsy, immunophenotyping, cytogenetic analysis, and molecular genetic testing.
6. Treated with intensive multi-agent chemotherapy regimens, often combined with radiation therapy and/or stem cell transplantation to achieve remission and improve survival outcomes.

Brachytherapy is a type of cancer treatment that involves placing radioactive material directly into or near the tumor site. The term "brachy" comes from the Greek word for "short," which refers to the short distance that the radiation travels. This allows for a high dose of radiation to be delivered directly to the tumor while minimizing exposure to healthy surrounding tissue.

There are two main types of brachytherapy:

1. Intracavitary brachytherapy: The radioactive material is placed inside a body cavity, such as the uterus or windpipe.
2. Interstitial brachytherapy: The radioactive material is placed directly into the tumor or surrounding tissue using needles, seeds, or catheters.

Brachytherapy can be used alone or in combination with other cancer treatments such as surgery, external beam radiation therapy, and chemotherapy. It may be recommended for a variety of cancers, including prostate, cervical, vaginal, vulvar, head and neck, and skin cancers. The specific type of brachytherapy used will depend on the size, location, and stage of the tumor.

The advantages of brachytherapy include its ability to deliver a high dose of radiation directly to the tumor while minimizing exposure to healthy tissue, which can result in fewer side effects compared to other forms of radiation therapy. Additionally, brachytherapy is often a shorter treatment course than external beam radiation therapy, with some treatments lasting only a few minutes or hours.

However, there are also potential risks and side effects associated with brachytherapy, including damage to nearby organs and tissues, bleeding, infection, and pain. Patients should discuss the benefits and risks of brachytherapy with their healthcare provider to determine if it is an appropriate treatment option for them.

Antineoplastic agents, alkylating, are a class of chemotherapeutic drugs that work by alkylating (adding alkyl groups) to DNA, which can lead to the death or dysfunction of cancer cells. These agents can form cross-links between strands of DNA, preventing DNA replication and transcription, ultimately leading to cell cycle arrest and apoptosis (programmed cell death). Examples of alkylating agents include cyclophosphamide, melphalan, and cisplatin. While these drugs are designed to target rapidly dividing cancer cells, they can also affect normal cells that divide quickly, such as those in the bone marrow and digestive tract, leading to side effects like anemia, neutropenia, thrombocytopenia, and nausea/vomiting.

Follicular lymphoma is a specific type of low-grade or indolent non-Hodgkin lymphoma (NHL). It develops from the B-lymphocytes, a type of white blood cell found in the lymphatic system. This lymphoma is characterized by the presence of abnormal follicles or nodules in the lymph nodes and other organs. The neoplastic cells in this subtype exhibit a distinct growth pattern that resembles normal follicular centers, hence the name "follicular lymphoma."

The majority of cases involve a translocation between chromosomes 14 and 18 [t(14;18)], leading to an overexpression of the BCL-2 gene. This genetic alteration contributes to the cancer cells' resistance to programmed cell death, allowing them to accumulate in the body.

Follicular lymphoma is typically slow-growing and may not cause symptoms for a long time. Common manifestations include painless swelling of lymph nodes, fatigue, weight loss, and night sweats. Treatment options depend on various factors such as the stage of the disease, patient's age, and overall health. Watchful waiting, chemotherapy, immunotherapy, targeted therapy, radiation therapy, or a combination of these approaches may be used to manage follicular lymphoma.

I'm sorry for any confusion, but "pyrazines" is not a term commonly used in medical definitions. Pyrazines are actually a class of organic compounds that contain a ring made up of two nitrogen atoms and three carbon atoms. They are found in various foods and contribute to their flavors. If you have any questions about organic chemistry or food science, I'd be happy to try to help!

Methotrexate is a medication used in the treatment of certain types of cancer and autoimmune diseases. It is an antimetabolite that inhibits the enzyme dihydrofolate reductase, which is necessary for the synthesis of purines and pyrimidines, essential components of DNA and RNA. By blocking this enzyme, methotrexate interferes with cell division and growth, making it effective in treating rapidly dividing cells such as cancer cells.

In addition to its use in cancer treatment, methotrexate is also used to manage autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In these conditions, methotrexate modulates the immune system and reduces inflammation.

It's important to note that methotrexate can have significant side effects and should be used under the close supervision of a healthcare provider. Regular monitoring of blood counts, liver function, and kidney function is necessary during treatment with methotrexate.

Ritonavir is an antiretroviral medication used in the treatment and prevention of HIV/AIDS. It is a protease inhibitor, which works by blocking the action of protease, an enzyme that the virus needs to multiply. By doing this, Ritonavir helps to reduce the amount of HIV in the body, keeping it at a low level and preventing the disease from progressing.

Ritonavir is often used in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART). It is also sometimes used at lower doses to boost the levels of other protease inhibitors in the body, a practice known as "pharmacologic boosting."

It's important to note that Ritonavir does not cure HIV/AIDS, but it can help people with HIV live longer, healthier lives. As with all medications, Ritonavir can have side effects, and it may interact with other drugs, so it's important to take it exactly as prescribed by a healthcare provider.

Organophosphonates are a class of organic compounds characterized by the presence of a carbon-phosphorus bond. They contain a phosphonic acid group, which consists of a phosphorus atom bonded to four oxygen or nitrogen atoms, with one of those bonds being replaced by a carbon atom.

In a medical context, organophosphonates are commonly used as radiopharmaceuticals in diagnostic nuclear medicine procedures, such as bone scans. These compounds have the ability to bind to hydroxyapatite, the mineral component of bones, and can be labeled with radioactive isotopes for imaging purposes. They may also be used in therapeutic settings, including as treatments for conditions such as tumor-induced hypercalcemia and Paget's disease of bone.

It is important to note that organophosphonates are distinct from organophosphates, another class of compounds that contain a phosphorus atom bonded to three oxygen or sulfur atoms and one carbon atom. Organophosphates have been widely used as pesticides and chemical warfare agents, and can pose significant health risks due to their toxicity.

Prostatic neoplasms refer to abnormal growths in the prostate gland, which can be benign or malignant. The term "neoplasm" simply means new or abnormal tissue growth. When it comes to the prostate, neoplasms are often referred to as tumors.

Benign prostatic neoplasms, such as prostate adenomas, are non-cancerous overgrowths of prostate tissue. They usually grow slowly and do not spread to other parts of the body. While they can cause uncomfortable symptoms like difficulty urinating, they are generally not life-threatening.

Malignant prostatic neoplasms, on the other hand, are cancerous growths. The most common type of prostate cancer is adenocarcinoma, which arises from the glandular cells in the prostate. Prostate cancer often grows slowly and may not cause any symptoms for many years. However, some types of prostate cancer can be aggressive and spread quickly to other parts of the body, such as the bones or lymph nodes.

It's important to note that while prostate neoplasms can be concerning, early detection and treatment can significantly improve outcomes for many men. Regular check-ups with a healthcare provider are key to monitoring prostate health and catching any potential issues early on.

"Drug evaluation" is a medical term that refers to the systematic process of assessing the pharmacological, therapeutic, and safety profile of a drug or medication. This process typically involves several stages, including preclinical testing in the laboratory, clinical trials in human subjects, and post-marketing surveillance.

The goal of drug evaluation is to determine the efficacy, safety, and optimal dosage range of a drug, as well as any potential interactions with other medications or medical conditions. The evaluation process also includes an assessment of the drug's pharmacokinetics, or how it is absorbed, distributed, metabolized, and eliminated by the body.

The findings from drug evaluations are used to inform regulatory decisions about whether a drug should be approved for use in clinical practice, as well as to provide guidance to healthcare providers about how to use the drug safely and effectively.

Vascular patency is a term used in medicine to describe the state of a blood vessel (such as an artery or vein) being open, unobstructed, and allowing for the normal flow of blood. It is an important concept in the treatment and management of various cardiovascular conditions, such as peripheral artery disease, coronary artery disease, and deep vein thrombosis.

Maintaining vascular patency can help prevent serious complications like tissue damage, organ dysfunction, or even death. This may involve medical interventions such as administering blood-thinning medications to prevent clots, performing procedures to remove blockages, or using devices like stents to keep vessels open. Regular monitoring of vascular patency is also crucial for evaluating the effectiveness of treatments and adjusting care plans accordingly.

Androgen antagonists are a class of drugs that block the action of androgens, which are hormones that contribute to male sexual development and characteristics. They work by binding to androgen receptors in cells, preventing the natural androgens from attaching and exerting their effects. This can be useful in treating conditions that are caused or worsened by androgens, such as prostate cancer, hirsutism (excessive hair growth in women), and acne. Examples of androgen antagonists include flutamide, bicalutamide, and spironolactone.

Intravenous (IV) infusion is a medical procedure in which liquids, such as medications, nutrients, or fluids, are delivered directly into a patient's vein through a needle or a catheter. This route of administration allows for rapid absorption and distribution of the infused substance throughout the body. IV infusions can be used for various purposes, including resuscitation, hydration, nutrition support, medication delivery, and blood product transfusion. The rate and volume of the infusion are carefully controlled to ensure patient safety and efficacy of treatment.

Peripheral Blood Stem Cell Transplantation (PBSCT) is a medical procedure that involves the transplantation of stem cells, which are immature cells found in the bone marrow that can develop into different types of blood cells. In PBSCT, these stem cells are collected from the peripheral blood instead of directly from the bone marrow.

The process begins with mobilization, where a growth factor medication is given to the donor to stimulate the release of stem cells from the bone marrow into the peripheral blood. After several days, the donor's blood is then removed through a procedure called apheresis, where the stem cells are separated and collected while the remaining blood components are returned to the donor.

The collected stem cells are then infused into the recipient's bloodstream, where they migrate to the bone marrow and begin to repopulate, leading to the production of new blood cells. This procedure is often used as a treatment for various malignant and non-malignant disorders, such as leukemia, lymphoma, multiple myeloma, and aplastic anemia.

PBSCT offers several advantages over traditional bone marrow transplantation, including faster engraftment, lower risk of graft failure, and reduced procedure-related morbidity. However, it also has its own set of challenges, such as the potential for increased incidence of chronic graft-versus-host disease (GVHD) and the need for more stringent HLA matching between donor and recipient.

Fluorouracil is a antineoplastic medication, which means it is used to treat cancer. It is a type of chemotherapy drug known as an antimetabolite. Fluorouracil works by interfering with the growth of cancer cells and ultimately killing them. It is often used to treat colon, esophageal, stomach, and breast cancers, as well as skin conditions such as actinic keratosis and superficial basal cell carcinoma. Fluorouracil may be given by injection or applied directly to the skin in the form of a cream.

It is important to note that fluorouracil can have serious side effects, including suppression of bone marrow function, mouth sores, stomach and intestinal ulcers, and nerve damage. It should only be used under the close supervision of a healthcare professional.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

HIV (Human Immunodeficiency Virus) infection is a viral illness that progressively attacks and weakens the immune system, making individuals more susceptible to other infections and diseases. The virus primarily infects CD4+ T cells, a type of white blood cell essential for fighting off infections. Over time, as the number of these immune cells declines, the body becomes increasingly vulnerable to opportunistic infections and cancers.

HIV infection has three stages:

1. Acute HIV infection: This is the initial stage that occurs within 2-4 weeks after exposure to the virus. During this period, individuals may experience flu-like symptoms such as fever, fatigue, rash, swollen glands, and muscle aches. The virus replicates rapidly, and the viral load in the body is very high.
2. Chronic HIV infection (Clinical latency): This stage follows the acute infection and can last several years if left untreated. Although individuals may not show any symptoms during this phase, the virus continues to replicate at low levels, and the immune system gradually weakens. The viral load remains relatively stable, but the number of CD4+ T cells declines over time.
3. AIDS (Acquired Immunodeficiency Syndrome): This is the most advanced stage of HIV infection, characterized by a severely damaged immune system and numerous opportunistic infections or cancers. At this stage, the CD4+ T cell count drops below 200 cells/mm3 of blood.

It's important to note that with proper antiretroviral therapy (ART), individuals with HIV infection can effectively manage the virus, maintain a healthy immune system, and significantly reduce the risk of transmission to others. Early diagnosis and treatment are crucial for improving long-term health outcomes and reducing the spread of HIV.

In medical terms, the leg refers to the lower portion of the human body that extends from the knee down to the foot. It includes the thigh (femur), lower leg (tibia and fibula), foot, and ankle. The leg is primarily responsible for supporting the body's weight and enabling movements such as standing, walking, running, and jumping.

The leg contains several important structures, including bones, muscles, tendons, ligaments, blood vessels, nerves, and joints. These structures work together to provide stability, support, and mobility to the lower extremity. Common medical conditions that can affect the leg include fractures, sprains, strains, infections, peripheral artery disease, and neurological disorders.

HIV-1 (Human Immunodeficiency Virus type 1) is a species of the retrovirus genus that causes acquired immunodeficiency syndrome (AIDS). It is primarily transmitted through sexual contact, exposure to infected blood or blood products, and from mother to child during pregnancy, childbirth, or breastfeeding. HIV-1 infects vital cells in the human immune system, such as CD4+ T cells, macrophages, and dendritic cells, leading to a decline in their numbers and weakening of the immune response over time. This results in the individual becoming susceptible to various opportunistic infections and cancers that ultimately cause death if left untreated. HIV-1 is the most prevalent form of HIV worldwide and has been identified as the causative agent of the global AIDS pandemic.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

The tibial arteries are three major arteries that supply blood to the lower leg and foot. They are branches of the popliteal artery, which is a continuation of the femoral artery. The three tibial arteries are:

1. Anterior tibial artery: This artery runs down the front of the leg and supplies blood to the muscles in the anterior compartment of the leg, as well as to the foot. It becomes the dorsalis pedis artery as it approaches the ankle.
2. Posterior tibial artery: This artery runs down the back of the leg and supplies blood to the muscles in the posterior compartment of the leg. It then branches into the fibular (peroneal) artery and the medial and lateral plantar arteries, which supply blood to the foot.
3. Fibular (peroneal) artery: This artery runs down the outside of the leg and supplies blood to the muscles in the lateral compartment of the leg. It also provides branches that anastomose with the anterior and posterior tibial arteries, forming a network of vessels that helps ensure adequate blood flow to the foot.

Together, these arteries play a critical role in providing oxygenated blood and nutrients to the lower leg and foot, helping to maintain their health and function.

Leukopenia is a medical term used to describe an abnormally low white blood cell (WBC) count in the blood. White blood cells are crucial components of the body's immune system, helping to fight infections and diseases. A normal WBC count ranges from 4,500 to 11,000 cells per microliter (μL) of blood in most laboratories. Leukopenia is typically diagnosed when the WBC count falls below 4,500 cells/μL.

There are several types of white blood cells, including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Neutropenia, a specific type of leukopenia, refers to an abnormally low neutrophil count (less than 1,500 cells/μL). Neutropenia increases the risk of bacterial and fungal infections since neutrophils play a significant role in combating these types of pathogens.

Leukopenia can result from various factors, such as viral infections, certain medications (like chemotherapy or radiation therapy), bone marrow disorders, autoimmune diseases, or congenital conditions affecting white blood cell production. It is essential to identify the underlying cause of leukopenia to provide appropriate treatment and prevent complications.

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL), which is a cancer of the lymphatic system. Specifically, MCL arises from abnormal B-lymphocytes (a type of white blood cell) that typically reside in the "mantle zone" of the lymph node. The malignant cells in MCL tend to have a characteristic genetic abnormality where the cyclin D1 gene is translocated to the immunoglobulin heavy chain gene locus, resulting in overexpression of cyclin D1 protein. This leads to uncontrolled cell division and proliferation.

Mantle cell lymphoma often presents with advanced-stage disease, involving multiple lymph nodes, bone marrow, and sometimes extranodal sites such as the gastrointestinal tract. Symptoms may include swollen lymph nodes, fatigue, weight loss, night sweats, and abdominal pain or discomfort.

Treatment for MCL typically involves a combination of chemotherapy, immunotherapy, and sometimes targeted therapy or stem cell transplantation. However, the prognosis for MCL is generally less favorable compared to other types of NHL, with a median overall survival of around 5-7 years.

Dacarbazine is a medical term that refers to a chemotherapeutic agent used in the treatment of various types of cancer. It is an alkylating agent, which means it works by modifying the DNA of cancer cells, preventing them from dividing and growing. Dacarbazine is often used to treat malignant melanoma, Hodgkin's lymphoma, and soft tissue sarcomas.

The drug is typically administered intravenously in a hospital or clinic setting, and the dosage and schedule may vary depending on the type and stage of cancer being treated, as well as the patient's overall health and response to treatment. Common side effects of dacarbazine include nausea, vomiting, loss of appetite, and weakness or fatigue. More serious side effects, such as low white blood cell counts, anemia, and liver damage, may also occur.

It is important for patients receiving dacarbazine to follow their doctor's instructions carefully and report any unusual symptoms or side effects promptly. Regular monitoring of blood counts and other laboratory tests may be necessary to ensure safe and effective treatment.

The Kaplan-Meier estimate is a statistical method used to calculate the survival probability over time in a population. It is commonly used in medical research to analyze time-to-event data, such as the time until a patient experiences a specific event like disease progression or death. The Kaplan-Meier estimate takes into account censored data, which occurs when some individuals are lost to follow-up before experiencing the event of interest.

The method involves constructing a survival curve that shows the proportion of subjects still surviving at different time points. At each time point, the survival probability is calculated as the product of the conditional probabilities of surviving from one time point to the next. The Kaplan-Meier estimate provides an unbiased and consistent estimator of the survival function, even when censoring is present.

In summary, the Kaplan-Meier estimate is a crucial tool in medical research for analyzing time-to-event data and estimating survival probabilities over time while accounting for censored observations.

Adjuvant radiotherapy is a type of cancer treatment that uses radiation therapy as an adjunct to a primary surgical procedure. The goal of adjuvant radiotherapy is to eliminate any remaining microscopic cancer cells that may be present in the surrounding tissues after surgery, thereby reducing the risk of local recurrence and improving the chances of cure.

Radiotherapy involves the use of high-energy radiation to destroy cancer cells and shrink tumors. In adjuvant radiotherapy, the radiation is usually delivered to the tumor bed and regional lymph nodes in order to target any potential sites of residual disease. The timing and dosing of adjuvant radiotherapy may vary depending on the type and stage of cancer being treated, as well as other factors such as patient age and overall health status.

Adjuvant radiotherapy is commonly used in the treatment of various types of cancer, including breast, colorectal, lung, head and neck, and gynecologic cancers. Its use has been shown to improve survival rates and reduce the risk of recurrence in many cases, making it an important component of comprehensive cancer care.

Monoclonal antibodies are laboratory-produced proteins that mimic the immune system's ability to fight off harmful antigens such as viruses and cancer cells. They are created by fusing a single B cell (the type of white blood cell responsible for producing antibodies) with a tumor cell, resulting in a hybrid cell called a hybridoma. This hybridoma can then be cloned to produce a large number of identical cells, all producing the same antibody, hence "monoclonal."

Humanized monoclonal antibodies are a type of monoclonal antibody that have been genetically engineered to include human components. This is done to reduce the risk of an adverse immune response in patients receiving the treatment. In this process, the variable region of the mouse monoclonal antibody, which contains the antigen-binding site, is grafted onto a human constant region. The resulting humanized monoclonal antibody retains the ability to bind to the target antigen while minimizing the immunogenicity associated with murine (mouse) antibodies.

In summary, "antibodies, monoclonal, humanized" refers to a type of laboratory-produced protein that mimics the immune system's ability to fight off harmful antigens, but with reduced immunogenicity due to the inclusion of human components in their structure.

Carboplatin is a chemotherapeutic agent used to treat various types of cancers, including ovarian, lung, and head and neck cancer. It is a platinum-containing compound that works by forming crosslinks in DNA, which leads to the death of rapidly dividing cells, such as cancer cells. Carboplatin is often used in combination with other chemotherapy drugs and is administered intravenously.

The medical definition of Carboplatin is:

"A platinum-containing antineoplastic agent that forms crosslinks with DNA, inducing cell cycle arrest and apoptosis. It is used to treat a variety of cancers, including ovarian, lung, and head and neck cancer."

Viral load refers to the amount or quantity of virus (like HIV, Hepatitis C, SARS-CoV-2) present in an individual's blood or bodily fluids. It is often expressed as the number of virus copies per milliliter of blood or fluid. Monitoring viral load is important in managing and treating certain viral infections, as a higher viral load may indicate increased infectivity, disease progression, or response to treatment.

Neutropenia is a condition characterized by an abnormally low concentration (less than 1500 cells/mm3) of neutrophils, a type of white blood cell that plays a crucial role in fighting off bacterial and fungal infections. Neutrophils are essential components of the innate immune system, and their main function is to engulf and destroy microorganisms that can cause harm to the body.

Neutropenia can be classified as mild, moderate, or severe based on the severity of the neutrophil count reduction:

* Mild neutropenia: Neutrophil count between 1000-1500 cells/mm3
* Moderate neutropenia: Neutrophil count between 500-1000 cells/mm3
* Severe neutropenia: Neutrophil count below 500 cells/mm3

Severe neutropenia significantly increases the risk of developing infections, as the body's ability to fight off microorganisms is severely compromised. Common causes of neutropenia include viral infections, certain medications (such as chemotherapy or antibiotics), autoimmune disorders, and congenital conditions affecting bone marrow function. Treatment for neutropenia typically involves addressing the underlying cause, administering granulocyte-colony stimulating factors to boost neutrophil production, and providing appropriate antimicrobial therapy to prevent or treat infections.

Antineoplastic agents, phytogenic, also known as plant-derived anticancer drugs, are medications that are derived from plants and used to treat cancer. These agents have natural origins and work by interfering with the growth and multiplication of cancer cells, helping to slow or stop the spread of the disease. Some examples of antineoplastic agents, phytogenic include paclitaxel (Taxol), vincristine, vinblastine, and etoposide. These drugs are often used in combination with other treatments such as surgery, radiation therapy, and other medications to provide a comprehensive approach to cancer care.

Infection is defined medically as the invasion and multiplication of pathogenic microorganisms such as bacteria, viruses, fungi, or parasites within the body, which can lead to tissue damage, illness, and disease. This process often triggers an immune response from the host's body in an attempt to eliminate the infectious agents and restore homeostasis. Infections can be transmitted through various routes, including airborne particles, direct contact with contaminated surfaces or bodily fluids, sexual contact, or vector-borne transmission. The severity of an infection may range from mild and self-limiting to severe and life-threatening, depending on factors such as the type and quantity of pathogen, the host's immune status, and any underlying health conditions.

Pyrimidines are heterocyclic aromatic organic compounds similar to benzene and pyridine, containing two nitrogen atoms at positions 1 and 3 of the six-member ring. They are one of the two types of nucleobases found in nucleic acids, the other being purines. The pyrimidine bases include cytosine (C) and thymine (T) in DNA, and uracil (U) in RNA, which pair with guanine (G) and adenine (A), respectively, through hydrogen bonding to form the double helix structure of nucleic acids. Pyrimidines are also found in many other biomolecules and have various roles in cellular metabolism and genetic regulation.

Paclitaxel is a chemotherapeutic agent derived from the bark of the Pacific yew tree (Taxus brevifolia). It is an antimicrotubule agent that promotes the assembly and stabilization of microtubules, thereby interfering with the normal dynamic reorganization of the microtubule network that is essential for cell division.

Paclitaxel is used in the treatment of various types of cancer including ovarian, breast, lung, and pancreatic cancers. It works by inhibiting the disassembly of microtubules, which prevents the separation of chromosomes during mitosis, leading to cell cycle arrest and apoptosis (programmed cell death).

Common side effects of paclitaxel include neutropenia (low white blood cell count), anemia (low red blood cell count), alopecia (hair loss), peripheral neuropathy (nerve damage causing numbness or tingling in the hands and feet), myalgias (muscle pain), arthralgias (joint pain), and hypersensitivity reactions.

Autologous blood transfusion is a medical procedure in which a patient receives their own blood that has been collected and stored prior to surgery or a medical treatment that may cause significant blood loss. The blood is drawn from the patient, typically in the days or weeks leading up to the scheduled procedure, and then stored until it is needed during or after the surgery.

The primary advantage of autologous blood transfusion is that it eliminates the risk of transfusion reactions, infectious disease transmission, and immunomodulation associated with allogeneic (donor) blood transfusions. However, not all patients are candidates for this type of transfusion due to various factors such as medical conditions, low hemoglobin levels, or insufficient time to collect and store the blood before the procedure.

Autologous blood transfusion can be performed using several methods, including preoperative blood donation, acute normovolemic hemodilution, intraoperative cell salvage, and postoperative blood collection. The choice of method depends on various factors, such as the patient's medical condition, the type and extent of surgery, and the availability of resources.

In summary, autologous blood transfusion is a safe and effective way to reduce the need for allogeneic blood transfusions during or after surgical procedures, but it may not be suitable for all patients.

A feasibility study is a preliminary investigation or analysis conducted to determine the viability of a proposed project, program, or product. In the medical field, feasibility studies are often conducted before implementing new treatments, procedures, equipment, or facilities. These studies help to assess the practicality and effectiveness of the proposed intervention, as well as its potential benefits and risks.

Feasibility studies in healthcare typically involve several steps:

1. Problem identification: Clearly define the problem that the proposed project, program, or product aims to address.
2. Objectives setting: Establish specific, measurable, achievable, relevant, and time-bound (SMART) objectives for the study.
3. Literature review: Conduct a thorough review of existing research and best practices related to the proposed intervention.
4. Methodology development: Design a methodology for data collection and analysis that will help answer the research questions and achieve the study's objectives.
5. Resource assessment: Evaluate the availability and adequacy of resources, including personnel, time, and finances, required to carry out the proposed intervention.
6. Risk assessment: Identify potential risks and challenges associated with the implementation of the proposed intervention and develop strategies to mitigate them.
7. Cost-benefit analysis: Estimate the costs and benefits of the proposed intervention, including direct and indirect costs, as well as short-term and long-term benefits.
8. Stakeholder engagement: Engage relevant stakeholders, such as patients, healthcare providers, administrators, and policymakers, to gather their input and support for the proposed intervention.
9. Decision-making: Based on the findings of the feasibility study, make an informed decision about whether or not to proceed with the proposed project, program, or product.

Feasibility studies are essential in healthcare as they help ensure that resources are allocated efficiently and effectively, and that interventions are evidence-based, safe, and beneficial for patients.

A CD4 lymphocyte count is a laboratory test that measures the number of CD4 T-cells (also known as CD4+ T-cells or helper T-cells) in a sample of blood. CD4 cells are a type of white blood cell that plays a crucial role in the body's immune response, particularly in fighting off infections caused by viruses and other pathogens.

CD4 cells express a protein on their surface called the CD4 receptor, which is used by human immunodeficiency virus (HIV) to infect and destroy these cells. As a result, people with HIV infection or AIDS often have low CD4 lymphocyte counts, which can make them more susceptible to opportunistic infections and other complications.

A normal CD4 lymphocyte count ranges from 500 to 1,200 cells per cubic millimeter of blood (cells/mm3) in healthy adults. A lower than normal CD4 count is often used as a marker for the progression of HIV infection and the development of AIDS. CD4 counts are typically monitored over time to assess the effectiveness of antiretroviral therapy (ART) and to guide clinical decision-making regarding the need for additional interventions, such as prophylaxis against opportunistic infections.

Camptothecin is a topoisomerase I inhibitor, which is a type of chemotherapeutic agent used in cancer treatment. It works by interfering with the function of an enzyme called topoisomerase I, which helps to uncoil DNA during cell division. By inhibiting this enzyme, camptothecin prevents the cancer cells from dividing and growing, ultimately leading to their death.

Camptothecin is found naturally in the bark and stem of the Camptotheca acuminata tree, also known as the "happy tree," which is native to China. It was first isolated in 1966 and has since been developed into several synthetic derivatives, including irinotecan and topotecan, which are used clinically to treat various types of cancer, such as colon, lung, and ovarian cancers.

Like other chemotherapeutic agents, camptothecin can have significant side effects, including nausea, vomiting, diarrhea, and myelosuppression (suppression of bone marrow function). It is important for patients receiving camptothecin-based therapies to be closely monitored by their healthcare team to manage these side effects effectively.

Antimetabolites are a class of antineoplastic (chemotherapy) drugs that interfere with the metabolism of cancer cells and inhibit their growth and proliferation. These agents are structurally similar to naturally occurring metabolites, such as amino acids, nucleotides, and folic acid, which are essential for cellular replication and growth. Antimetabolites act as false analogs and get incorporated into the growing cells' DNA or RNA, causing disruption of the normal synthesis process, leading to cell cycle arrest and apoptosis (programmed cell death).

Examples of antimetabolite drugs include:

1. Folate antagonists: Methotrexate, Pemetrexed
2. Purine analogs: Mercaptopurine, Thioguanine, Fludarabine, Cladribine
3. Pyrimidine analogs: 5-Fluorouracil (5-FU), Capecitabine, Cytarabine, Gemcitabine

These drugs are used to treat various types of cancers, such as leukemias, lymphomas, breast, ovarian, and gastrointestinal cancers. Due to their mechanism of action, antimetabolites can also affect normal, rapidly dividing cells in the body, leading to side effects like myelosuppression (decreased production of blood cells), mucositis (inflammation and ulceration of the gastrointestinal tract), and alopecia (hair loss).

Clinical trials are research studies that involve human participants and are designed to evaluate the safety and efficacy of new medical treatments, drugs, devices, or behavioral interventions. The purpose of clinical trials is to determine whether a new intervention is safe, effective, and beneficial for patients, as well as to compare it with currently available treatments. Clinical trials follow a series of phases, each with specific goals and criteria, before a new intervention can be approved by regulatory authorities for widespread use.

Clinical trials are conducted according to a protocol, which is a detailed plan that outlines the study's objectives, design, methodology, statistical analysis, and ethical considerations. The protocol is developed and reviewed by a team of medical experts, statisticians, and ethicists, and it must be approved by an institutional review board (IRB) before the trial can begin.

Participation in clinical trials is voluntary, and participants must provide informed consent before enrolling in the study. Informed consent involves providing potential participants with detailed information about the study's purpose, procedures, risks, benefits, and alternatives, as well as their rights as research subjects. Participants can withdraw from the study at any time without penalty or loss of benefits to which they are entitled.

Clinical trials are essential for advancing medical knowledge and improving patient care. They help researchers identify new treatments, diagnostic tools, and prevention strategies that can benefit patients and improve public health. However, clinical trials also pose potential risks to participants, including adverse effects from experimental interventions, time commitment, and inconvenience. Therefore, it is important for researchers to carefully design and conduct clinical trials to minimize risks and ensure that the benefits outweigh the risks.

Acute myeloid leukemia (AML) is a type of cancer that originates in the bone marrow, the soft inner part of certain bones where new blood cells are made. In AML, the immature cells, called blasts, in the bone marrow fail to mature into normal blood cells. Instead, these blasts accumulate and interfere with the production of normal blood cells, leading to a shortage of red blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells (leukopenia).

AML is called "acute" because it can progress quickly and become severe within days or weeks without treatment. It is a type of myeloid leukemia, which means that it affects the myeloid cells in the bone marrow. Myeloid cells are a type of white blood cell that includes monocytes and granulocytes, which help fight infection and defend the body against foreign invaders.

In AML, the blasts can build up in the bone marrow and spread to other parts of the body, including the blood, lymph nodes, liver, spleen, and brain. This can cause a variety of symptoms, such as fatigue, fever, frequent infections, easy bruising or bleeding, and weight loss.

AML is typically treated with a combination of chemotherapy, radiation therapy, and/or stem cell transplantation. The specific treatment plan will depend on several factors, including the patient's age, overall health, and the type and stage of the leukemia.

Radiotherapy dosage refers to the total amount of radiation energy that is absorbed by tissues or organs, typically measured in units of Gray (Gy), during a course of radiotherapy treatment. It is the product of the dose rate (the amount of radiation delivered per unit time) and the duration of treatment. The prescribed dosage for cancer treatments can range from a few Gray to more than 70 Gy, depending on the type and location of the tumor, the patient's overall health, and other factors. The goal of radiotherapy is to deliver a sufficient dosage to destroy the cancer cells while minimizing damage to surrounding healthy tissues.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Lamivudine is an antiretroviral medication used in the treatment and management of HIV (Human Immunodeficiency Virus) infection and HBV (Hepatitis B Virus) infection. It is a nucleoside reverse transcriptase inhibitor (NRTI), which means it works by blocking the action of the reverse transcriptase enzyme that the viruses need to multiply. By doing this, Lamivudine helps to reduce the amount of the virus in the body, which in turn helps to slow down or prevent the damage that the virus can cause to the immune system and improve the patient's quality of life.

The medical definition of Lamivudine is: "A synthetic nucleoside analogue with activity against both HIV-1 and HBV. It is used in the treatment of HIV infection and AIDS, as well as chronic hepatitis B."

Reverse Transcriptase Inhibitors (RTIs) are a class of antiretroviral drugs that are primarily used in the treatment and management of HIV (Human Immunodeficiency Virus) infection. They work by inhibiting the reverse transcriptase enzyme, which is essential for the replication of HIV.

HIV is a retrovirus, meaning it has an RNA genome and uses a unique enzyme called reverse transcriptase to convert its RNA into DNA. This process is necessary for the virus to integrate into the host cell's genome and replicate. Reverse Transcriptase Inhibitors interfere with this process by binding to the reverse transcriptase enzyme, preventing it from converting the viral RNA into DNA.

RTIs can be further divided into two categories: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). NRTIs are analogs of the building blocks of DNA, which get incorporated into the growing DNA chain during replication, causing termination of the chain. NNRTIs bind directly to the reverse transcriptase enzyme, causing a conformational change that prevents it from functioning.

By inhibiting the reverse transcriptase enzyme, RTIs can prevent the virus from replicating and reduce the viral load in an infected individual, thereby slowing down the progression of HIV infection and AIDS (Acquired Immunodeficiency Syndrome).

A reoperation is a surgical procedure that is performed again on a patient who has already undergone a previous operation for the same or related condition. Reoperations may be required due to various reasons, such as inadequate initial treatment, disease recurrence, infection, or complications from the first surgery. The nature and complexity of a reoperation can vary widely depending on the specific circumstances, but it often carries higher risks and potential complications compared to the original operation.

The term "lower extremity" is used in the medical field to refer to the portion of the human body that includes the structures below the hip joint. This includes the thigh, lower leg, ankle, and foot. The lower extremities are responsible for weight-bearing and locomotion, allowing individuals to stand, walk, run, and jump. They contain many important structures such as bones, muscles, tendons, ligaments, nerves, and blood vessels.

Amphotericin B is an antifungal medication used to treat serious and often life-threatening fungal infections. It works by binding to the ergosterol in the fungal cell membrane, creating pores that lead to the loss of essential cell components and ultimately cell death.

The medical definition of Amphotericin B is:

A polyene antifungal agent derived from Streptomyces nodosus, with a broad spectrum of activity against various fungi, including Candida, Aspergillus, Cryptococcus, and Histoplasma capsulatum. Amphotericin B is used to treat systemic fungal infections, such as histoplasmosis, cryptococcosis, candidiasis, and aspergillosis, among others. It may be administered intravenously or topically, depending on the formulation and the site of infection.

Adverse effects associated with Amphotericin B include infusion-related reactions (such as fever, chills, and hypotension), nephrotoxicity, electrolyte imbalances, and anemia. These side effects are often dose-dependent and may be managed through careful monitoring and adjustment of the dosing regimen.

... , also known as rescue therapy, is a form of therapy given after an ailment does not respond to standard therapy ... Salvage therapy drugs or drug combinations have, in general, much more severe side effects than the standard line of therapy. ... "Antiretroviral Therapy (ART)". World Health Organization. 2006. Retrieved 2006-10-26. "SALVAGE THERAPY". The AIDS InfoNet. 2006 ... Heroic measure Linda Grinberg "Definition of Salvage therapy". MedicineNet.com. 2006. Retrieved 2006-10-26. "HIV Therapy 2006 ...
Wedemeyer, Christian; Kauther, Max Daniel (2011-03-16). "Hemipelvectomy- only a salvage therapy?". Orthopedic Reviews. 3 (1): ...
SIRT is currently considered as a salvage therapy. It has been shown to be safe and effective in patients for whom surgery is ... establishing the safety of the therapy. More recently, larger trials and RCTs have shown safety and efficacy of 90Y therapy for ... Radiation therapy is used to kill cancer cells; however, normal cells are also damaged in the process. Currently, therapeutic ... "Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer - Full Text View - ...
He also introduced drug development strategies for salvage therapy, and discussed the conflicts and solutions regarding this. ... "Drug development strategies for salvage therapy: conflicts and solutions". AIDS Research and Human Retroviruses. 22 (11): 1106- ... He has also authored several books and textbooks, including Protease Inhibitors in AIDS Therapy, Integrative Pharmacology, ... Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naïve patients: results of AIDS ...
Fuzeon (enfuvirtide), for salvage therapy of HIV-1 infection. Gazyva (obinutuzumab), for chronic lymphocytic leukaemia. ... A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an ... In 1995, the era of highly active anti-retroviral therapy (HAART) was initiated by the United States FDA's approval of Hoffman ... "Roche 'steps up' for gene therapy with $4.3 billion Spark bet". Reuters.com. Reuters. 25 February 2019. "Roche says its $4.3 ...
It is not considered a first-line treatment, but it can be useful as salvage therapy. It also has the advantage of being less ... Chan JK, Loizzi V, Manetta A, Berman ML (January 2004). "Oral altretamine used as salvage therapy in recurrent ovarian cancer ... Malik IA (February 2001). "Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer ... a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy ...
"Confronting an Unaddressed Nigerian Reality in the Exhibition 'Salvage Therapy' , By Ayò Akínwándé". The Sole Adventurer. 2018- ... 2018 Confronting an Unaddressed Nigerian Reality in the Exhibition 'Salvage Therapy' The Sole Adventurer. 2020 "Who Art ...
When primary or secondary resistance invariably develops, salvage therapy is considered. Allogeneic stem cell transplantation ... They recommended starting therapy in patients with constitutional symptoms such as recurrent fever, night sweats, fatigue due ... Gertz MA (2005). "Waldenstrom macroglobulinemia: a review of therapy". Am J Hematol. 79 (2): 147-57. doi:10.1002/ajh.20363. ... However, CXCR4 mutation is not associated with splenomegaly, high platelet counts, or different response to therapy, ...
She served on the board of Project Inform, was founder of the Coalition for Salvage Therapy, co-founder of the FAIR Pricing ... James, John S. (November 5, 1999). "Activism today: the Coalition for Salvage Therapy: Interview with Linda Grinberg". AIDS ... concerned for expediting new treatments for AIDS and ensuring access to experimental therapies, especially for late-stage ...
August 2001). "Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia". Onkologie. 24 (4): 356-60. doi ...
Summerfield DT, Desai H, Levitov A, Grooms DA, Marik PE (2011). "Inhaled Nitric Oxide as Salvage Therapy in Massive ... Nitric oxide is also administered as salvage therapy in patients with acute right ventricular failure secondary to pulmonary ... It is used on an individualized basis in ICUs as an adjunct to other definitive therapies for reversible causes of hypoxemic ... This research is based on the fact that nitric oxide was investigated as an experimental therapy for SARS. Brian Strickland, MD ...
other antibiotics, such as minocycline, have seen some use as a salvage therapy). If infected during pregnancy, spiramycin is ... Combination therapy is most useful in the setting of HIV. Clindamycin Spiramycin - an antibiotic used most often for pregnant ... As a result, the possibility of an alternative diagnosis is supported by a failed trial of antimicrobial therapy (pyrimethamine ... an antibiotic used in combination with pyrimethamine to treat toxoplasmosis Combination therapy is usually given with folic ...
Per Montag's request to salvage their relationship, Pratt agreed to attend couples' therapy. As they became re-engaged and ...
Voriconazole is also being studied in salvage therapy for refractory cases. A case report indicated that voriconazole in ... Posaconazole has been approved by the European Commission as a salvage therapy for refractory coccidioidomycosis. Clinical ... The duration of therapy is dictated by the clinical course of the illness, but it should be at least 6 months in all patients ... Therapy is tailored based on a combination of resolution of symptoms, regression of radiographic abnormalities, and changes in ...
The treatments include surgery, chemotherapy, radiation therapy, targeted therapy, salvage therapy, and clinical trials. Among ... Salvage Therapy: this treatment is given if there is no response to previous treatments. Clinical Trials: the follow-up study ... February 2014). "Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience". Pediatric ... "Radiation Therapy". National Cancer Institute. 2015-04-29. Retrieved 2019-05-27. "Understanding Targeted Therapy". Cancer.Net. ...
van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP (2006). "Posaconazole is effective as salvage therapy in ... analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent ...
Intraoperative radiation therapy and intraoperative blood salvage may also be performed during this time. The postoperative ...
2006). "Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance". Antiviral Therapy. 11 ... Foscarnet can be used to treat highly treatment-experienced patients with HIV as part of salvage therapy. Foscarnet is a ... "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 ... Mathiesen S, Dam E, Roge B, Joergensen LB, Laursen AL, Gerstoft J, Clavel F (2007). "Long-term foscarnet therapy remodels ...
"Refractory Craniofacial Actinomycetoma Due to Streptomyces somaliensis That Required Salvage Therapy with Amikacin and Imipenem ...
"Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency ... Occasionally, minocycline therapy may result in autoimmune disorders such as drug-related lupus and autoimmune hepatitis, which ... Copeland KF, Brooks JI (April 2010). "A novel use for an old drug: the potential for minocycline as anti-HIV adjuvant therapy ... Autoimmune problems emerge during chronic therapy, but can sometimes occur after only short courses of a couple of weeks of ...
Small studies have also examined its use as salvage therapy for non-tuberculous mycobacterial infections. It is a component of ... "Two new drug therapies might cure every form of tuberculosis". New Scientist. Archived from the original on 20 February 2017. ...
... and Salvage Radiation Therapy for Cutaneous Squamous Cell Carcinoma". Dermatologic Surgery. 47 (5): 587-592. doi:10.1097/DSS. ... Radiation therapy is often used afterward in high risk cancer or patient types. Radiation or radiotherapy can also be a ... Radiotherapy Adjuvant therapy may be considered in those with high-risk cSCC even in the absence of evidence for local ... An example of this kind of therapy is the high-dose brachytherapy Rhenium-SCT which makes use of the beta rays emitting ...
These include: Visual Representations: Past and Present Artist-At-Work Artist Talk Salvage Art Therapy Exhibition. Power Show ...
"Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in ...
... may delay cell death and allow for greater salvage of myocardium through reperfusion therapy. AICAR has been shown to ... as a targeting agent for therapy of patients with acute lymphoblastic leukemia: are we there and are there pitfalls?". Journal ...
Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with drug resistance. However ... It is administered with ritonavir in combination therapy to treat HIV infection.[citation needed] Tipranavir has the ability to ...
They are also useful in salvage therapy for patients whose virus has mutated and acquired resistance to other drugs.[citation ... raltegravir plus optimized background therapy provided better viral suppression than optimized background therapy alone for at ... USA (2014). "Antiretroviral Therapy: Current Drugs". Infectious Disease Clinics of North America. Ncbi.nlm.nih.gov. 28 (3): 371 ... July 2008). "Raltegravir with optimized background therapy for resistant HIV-1 infection". N. Engl. J. Med. 359 (4): 339-54. ...
Caspofungin is used in the treatment of febrile neutropenia and as "salvage" therapy for the treatment of invasive ...
It is used in select situations, for instance as a salvage therapy in severe complicated cases or in other situations. One ... Kim C, Catanzariti AR, Mendicino RW (April 2009). "Tibiotalocalcaneal arthrodesis for salvage of severe ankle degeneration". ...
A local resident salvaged materials from a discarded radiation therapy machine containing 6,010 pellets of cobalt-60. The ... September 13, 1987 - In the Goiânia accident, scavengers broke open a radiation-therapy machine in an abandoned clinic in ...
Salvage therapy, also known as rescue therapy, is a form of therapy given after an ailment does not respond to standard therapy ... Salvage therapy drugs or drug combinations have, in general, much more severe side effects than the standard line of therapy. ... "Antiretroviral Therapy (ART)". World Health Organization. 2006. Retrieved 2006-10-26. "SALVAGE THERAPY". The AIDS InfoNet. 2006 ... Heroic measure Linda Grinberg "Definition of Salvage therapy". MedicineNet.com. 2006. Retrieved 2006-10-26. "HIV Therapy 2006 ...
... May 1, 2002. Publication ... Our conclusion is that ZD1839 is active as second-line or third-line therapy for NSCLC. It does improve quality of life. It ... Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non-Small-Cell Lung Cancer. September 18th 2018 ... Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non-Small-Cell Lung Cancer. September 18th 2018 ...
Salvage Radical Prostatectomy for Recurrent Prostate Cancer after Radiation Therapy. I often discuss the use of salvage ... When I first was deciding what to use as my primary treatment modality I was led to believe that salvage surgery could not be ... In reality a salvage radical prostatectomy can be considered for men with locally recurrent prostate cancer after external beam ... Although often mentioned, but seldom used, men who fail radiation as a primary treatment can also benefit from salvage surgery ...
Surgical and nonsurgical salvage therapies for local recurrence of prostate cancer following radiation treatment offer similar ... A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Published ... Surgical and nonsurgical local salvage treatments for prostate cancer (PCa) that recurs following radiation therapy offer ... Close more info about Salvage Therapies for Radiorecurrent Prostate Cancer Offer Similar RFS ...
... adverse features should undergo immediate adjuvant RT versus initial observation with more selective-but early-salvage RT in ... is evaluating salvage RT versus salvage RT to prostate bed plus 4 to 6 months of hormonal therapy, versus salvage RT to ... 397 received no salvage treatment, 160 received salvage RT alone, and 78 received salvage RT combined with hormonal therapy. ... salvage therapy. From Trock BJ. Han M, Freedland SJ, et al. Prostate-specific survival following salvage radiotherapy vs ...
Monk, EJM, Harris, C, Döffinger, R, Hayes, G, Denning, DW & Kosmidis, C 2020, Interferon gamma replacement as salvage therapy ... Dive into the research topics of Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis; effects ... Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis; effects on frequency of acute exacerbation ... Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis; effects on frequency of acute exacerbation ...
poly-therapy in recurrent disease, and whether molecular subgrouping of MB influences salvage therapy. This systematic review ... The aim of this systematic review will be to investigate the efficacy and safety of salvage therapies for the management of ... By reviewing the efficacy and toxicity of MB salvage therapies, this study will identify effective therapeutic strategies ... Despite best current therapies, patients with recurrent MB experience have an alarmingly high mortality rate and often have ...
Penumbra salvage in extensive stroke: exploring limits for reperfusion therapy.. Gabriel Broocks, Lukas Meyer, Matthias ... Penumbra salvage volume (PSV) has been described as a tool to measure the volume of rescued penumbra.. OBJECTIVE: To assess ... Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it.Seung-Jae JooAcute and critical ... CONCLUSIONS: Recanalization was associated with significant penumbra salvage up to a lower ASPECTS margin of 3 and upper core ...
Salvage therapy. Many of the regimens listed above that were not used as initial therapy can be considered as a salvage ... When selecting initial and salvage therapies for patients who may eventually be considered for autologous SCT, exposure to stem ... Maintenance therapy. The role of maintenance therapy in patients with WM/LPL remains controversial, as there are no prospective ... What are the regimens used in salvage therapy for Waldenstrom macroglobulinemia (WM)? ...
Shah, D. K., Zhang, W. X., Forman, D. L., Prabhat, A., Urken, M. L., & Weinberg, H. (1996). Combination therapy for salvaging a ... Combination therapy for salvaging a failing, experimental skin flap. Darsit K. Shah, Wen X. Zhang, Douglas L. Forman, Arvind ... Combination therapy for salvaging a failing, experimental skin flap. / Shah, Darsit K.; Zhang, Wen X.; Forman, Douglas L. et al ... Combination therapy for salvaging a failing, experimental skin flap. In: Journal of Reconstructive Microsurgery. 1996 ; Vol. 12 ...
Regorafenib and TFTD+B are both standard salvage options for metastatic CRC. ... the results are in line with previous reports for salvage regorafenib. ...
From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through ... From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through ... From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through ... From the Uncertainties to the Evidence : A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer ...
Whether focal therapy (FT) for prostate cancer (PC) jeopardizes outcomes from salvage treatments is a matter of debate still to ... While it seems that FT has a minimal impact on salvage treatment results, prospective controlled studies are needed to confirm ... Other options are radiation therapy (RT) and whole-gland or focal repeat ablations, although these have only been described ... Important limitations include the low level of the evidence and the absence of standardized criteria for FT, salvage treatment ...
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy a study on Colorectal Cancer Metastatic Cancer Colorectal Tumor ... Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study ... All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline ... Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible. ...
Some patients with R/R AML who do not respond to first-line venetoclax therapies may respond to chemotherapy intensification ... Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax based salvage therapies. Eur J Haematol. ... Close more info about Chemotherapy for Relapsed or Refracted Acute Myeloid Leukemia Unresponsive Venetoclax Salvage Therapy ... Close more info about Chemotherapy for Relapsed or Refracted Acute Myeloid Leukemia Unresponsive Venetoclax Salvage Therapy ...
Retrospective study shows an OS of 18 months with salvage therapies ... T-cell therapy can be salvaged with multiple lines of therapy, a retrospective study suggested. ... Retrospective study shows an OS of 18 months with salvage therapies. by Mike Bassett, Staff Writer, MedPage Today November 4, ... Achieving a partial response or better with the first line of salvage therapy was associated with a significantly longer median ...
A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond. 2022.02.09 ... Boron Neutron Capture Therapy Using Cyclotron-Based Epithermal Neutron Source and Borofalan(10B) for Recurrent or Locally ... Clinical Veterinary Boron Neutron Capture Therapy (BNCT) Studies in Dogs with Head and Neck Cancer:Bridging the Gap between ... Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have ...
... ... Background: Breast reconstruction after salvage mastectomy (SM) for recurrent cancer represents a challenge in preradiated ... Background: Breast reconstruction after salvage mastectomy (SM) for recurrent cancer represents a challenge in preradiated ... previously treated by partial mastectomy plus whole-breast radiation therapy, were analyzed. They underwent SM and immediate ...
Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB.. Abstract. New drugs are desperately ... Thioridazine has proven anti tuberculous effects in vitro and in vivo mouse models and we used this drug as salvage therapy in ... Because thioridazine has been used successfully for therapy of XDR-TB when in combination with antibiotics to which the ...
... or no response to or relapse after first salvage therapy or beyond) leukaemia. Patients received blinatumomab (9 μg/day for the ... Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy* * Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality ...
Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). Autologous ... Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). Autologous ... Although patients with late relapse (,12 months after completion of therapy) may be cured with conventional therapy, those with ... but randomized trials showing its superiority to conventional therapy are lacking. ...
Nightmares in Salvage Robot-assisted Radical Prostatectomy After Primary Radiation Therapy for Prostate Cancer: A Step by Step ... Salvage robot-assisted RP (sRARP) cases and imaging materials were used to create an educational video providing practical ... Salvage robot-assisted RP (sRARP) cases and imaging materials were used to create an educational video providing practical ... Salvage radical prostatectomy after primary radiotherapy (sRP) is considered a challenging procedure. We highlight the ...
Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae bacteremia; recent interferon-α therapy; salvage ...
Background: Salvage thoracoscopic esophagectomy after chemoradiation therapy is extremely difficult because of fibrotic and ... Dissection around trachea and bronchus in salvage thoracoscopic esophagectomy. Yusuke Taniyama, Tadashi Sakurai, Makoto Hikage ... Furthermore, tracheobronchial necrosis might happen in salvage esophagectomy if the surgeon did not pay much attention to ... Thus, we present the twists and methods of dissecting around trachea and bronchus in salvage thoracoscopic esophagectomy, ...
Salvage Radiation Therapy for Prostate Cancer Learn about salvage radiation therapy (SRT) as a type of cancer treatment given ... Androgen Deprivation Therapy (ADT) - What You Should Know Fact Sheet Learn about Androgen Deprivation Therapy (ADT) for ... Androgen Deprivation Therapy (ADT) - Talking to Your Doctor Fact Sheet Learn about how to talk to your doctor Androgen ... Bladder Cancer Treatment: Intravesical Therapy If you are a patient with non-muscle invasive bladder cancer, it is important to ...
Unexpectedly, attaining PR status was associated with a shorter time to salvage therapy for disease progression (P,.001), ... Unexpectedly, attaining PR status was associated with a shorter time to salvage therapy for disease progression (P,.001), ... Unexpectedly, attaining PR status was associated with a shorter time to salvage therapy for disease progression (P,.001), ... Unexpectedly, attaining PR status was associated with a shorter time to salvage therapy for disease progression (P,.001), ...
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy ... A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy ...
Old age and poor ECOG score were both poor prognostic factors in the salvage therapy. ... Retreatment with an EGFR TKI is not inferior to cytotoxic chemotherapy when used as salvage therapy for patients with ... Two hundred and nine patients with mutated EGFR and who took gefitinib as the first-line therapy were identified in the study ... Cytotoxic chemotherapy is regarded as being the standard therapy to overcome acquired resistance to an initial EGFR TKI. ...
E-148 Endovascular therapy in ischemic stroke with acute large vessel occlusion-recovery by endovascular salvage for cerebral ... E-148 Endovascular therapy in ischemic stroke with acute large vessel occlusion-recovery by endovascular salvage for cerebral ... Favorable outcomes were observed in 35.3% and 30.7% of patients in the endovascular therapy and no endovascular therapy groups ... Results A total of 2420 patients were recruited, 2399 (1,278 in endovascular therapy vs 1121 in no endovascular therapy) ...
  • In reality a salvage radical prostatectomy can be considered for men with locally recurrent prostate cancer after external beam radiotherapy has failed. (malecare.org)
  • 2 The argument for postoperative radiotherapy (RT) is predicated on the assumption that some patients may have residual local disease of a potentially lethal phenotype after surgery and that the delivery of secondary local therapy may interrupt the natural history of disease and prevent progression to systemic disease. (jnccn.org)
  • Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). (nih.gov)
  • Salvage radical prostatectomy after primary radiotherapy (sRP) is considered a challenging procedure. (unito.it)
  • Are all prostate cancer patients 'fit' for salvage radiotherapy? (wjgnet.com)
  • González-San Segundo C, Gómez-Iturriaga A, Couñago F. Are all prostate cancer patients "fit" for salvage radiotherapy? (wjgnet.com)
  • The indication for salvage radiotherapy (RT) (SRT) in patients with biochemically-recurrent prostate cancer after surgery is based on prostate-specific antigen (PSA) levels at the time of biochemical recurrence. (wjgnet.com)
  • Salvage surgery is considered an option for isolated recurrences of retroperitoneal and pelvic tumors , in patients who have undergone previous radiotherapy . (bvsalud.org)
  • Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. (ucl.ac.uk)
  • OBJECTIVE: To evaluate the role of prostate MRI in detection of prostate cancer recurring after radiotherapy and the role of salvage focal ablation in treating recurrent disease. (ucl.ac.uk)
  • Background: Disease progression following salvage radiotherapy (SRT) for prostate cancer (PC) is common, and the time to biochemical recurrence (BCR) is heterogeneous. (elsevierpure.com)
  • Patient summary: Many men will develop biochemical recurrence of prostate cancer after salvage radiotherapy. (elsevierpure.com)
  • Men with biochemical recurrence within 18 mo of salvage radiotherapy constitute a cohort at higher risk of distant metastasis and prostate cancer-specific mortality. (elsevierpure.com)
  • Salvage chemotherapy is a treatment that is given after the cancer has not responded to other chemotherapy regimens. (wikipedia.org)
  • Despite best current therapies, patients with recurrent MB experience have an alarmingly high mortality rate and often have limited therapeutic options beyond inadequate chemotherapy or experimental clinical trials. (biomedcentral.com)
  • Although applying multi-modal therapies (radiation, chemotherapy, and surgery) has increased 5-year survival amongst standard-risk MB patients, overall survival (OS) rates seem to have plateaued. (biomedcentral.com)
  • Bendamustine/rituximab is the preferred initial therapy for most patients, while ibrutinib/rituximab is an acceptable alternative for elderly patients who cannot tolerate chemotherapy. (medscape.com)
  • A small number of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) may benefit from chemotherapy intensification after not responding to venetoclax-based salvage therapy, according to a study published in the European Journal of Haematology . (hematologyadvisor.com)
  • Autologous HSCT following high-dose chemotherapy, the standard treatment for adult patients with relapsed HL, is also effective in paediatric patients, but randomized trials showing its superiority to conventional therapy are lacking. (nih.gov)
  • Epidermal growth factor receptor-tyrosine kinase inhibitors ( EGFR -TKIs) such as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than cytotoxic chemotherapy for metastatic lung non-squamous cell carcinoma harboring susceptible EGFR mutations when used as first-line therapy. (biomedcentral.com)
  • Cytotoxic chemotherapy is regarded as being the standard therapy to overcome acquired resistance to an initial EGFR TKI. (biomedcentral.com)
  • Two hundred and nine patients with mutated EGFR and who took gefitinib as the first-line therapy were identified in the study period, of whom 86 received second-line cytotoxic chemotherapy, and 60 who received third-line therapy were eligible for this study. (biomedcentral.com)
  • Retreatment with an EGFR TKI is not inferior to cytotoxic chemotherapy when used as salvage therapy for patients with adenocarcinoma with an EGFR mutation, especially if a third-generation EGFR TKI is not available, or if the reason for resistance is unknown or is not related to the T790M mutation. (biomedcentral.com)
  • According to study protocol, treatment was switched to salvage chemotherapy with the standard etoposide/cisplatin regimen etoposide/carboplatin (Par-aplatin) in some cases if tumor regression of less than 25% was seen following the first course. (cancernetwork.com)
  • Likewise, patients with tumor regression of less than 50% after the second course were switched to salvage chemotherapy. (cancernetwork.com)
  • Radical prostatectomy and nonsurgical salvage treatments for radiorecurrent prostate cancer offer similar 5-year recurrence-free survival rates, but toxicities appear less severe with high-dose-rate brachytherapy and stereotactic body radiation therapy, a meta-analysis found. (oncologynurseadvisor.com)
  • Surgical and nonsurgical local salvage treatments for prostate cancer (PCa) that recurs following radiation therapy offer similar 5-year recurrence-free survival (RFS) rates, but re-irradiation appears to result in less toxicity, according to a new meta-analysis. (oncologynurseadvisor.com)
  • The addition of IOERT to salvage resection for isolated recurrence of gynecologic cancers suggest favorable local control in cases with concern for residual microscopic disease . (bvsalud.org)
  • We find that many men will experience early biochemical recurrence following postprostatectomy salvage radiation therapy. (elsevierpure.com)
  • In explaining the rationale for the study, Parekh and colleagues noted that while the use of BCMA-directed CAR T-cell therapies in relapsed and refractory multiple myeloma have demonstrated high response rates, optimal treatment regimens have yet to be defined for patients who relapse. (medpagetoday.com)
  • however, risks associated with extravasation of Act-D and adverse effects such as alopecia and neutropenia make MTX regimens more commonly used as front-line therapy (see Table 1, below). (medscape.com)
  • Such information will lead providers to recommend off-label targeted therapy, which now routinely costs in excess of 100 000 dollars per year of treatment, [ 3 ] but the response rate to this strategy and whether it improves overall survival (OS) or progression-free survival (PFS) for these patients over alternative (typically cytotoxic) salvage regimens are currently unknown. (medscape.com)
  • Salvage Radical Prostatectomy for Recurrent Prostate Cancer after Radiation Therapy. (malecare.org)
  • Subsequently they were treated with salvage surgery for clinically localized prostate cancer once their PSA scores again began to rise. (malecare.org)
  • Reflecting this, the most recent update of the NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer states "new evidence supports offering adjuvant/salvage RT in all men with adverse pathologic features or detectable PSA" 3 (to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org ). (jnccn.org)
  • Salvage Local Treatments After Focal Therapy for Prostate Cancer. (endourology.ph)
  • Whether focal therapy (FT) for prostate cancer (PC) jeopardizes outcomes from salvage treatments is a matter of debate still to be resolved. (endourology.ph)
  • We performed a literature search to determine the treatment options available for prostate cancer after failure of focal therapy and their outcomes. (endourology.ph)
  • Learn about how to talk to your doctor Androgen Deprivation Therapy (ADT) for prostate cancer. (urologyhealth.org)
  • Learn about Androgen Deprivation Therapy (ADT) for prostate cancer, who should receive ADT, how is ADT given and the benefits, risks and side effects of ADT. (urologyhealth.org)
  • Learn about salvage radiation therapy (SRT) as a type of cancer treatment given to men who had their prostate removed yet their prostate-specific antigen (PSA) levels begin to rise. (urologyhealth.org)
  • Since measurable differences in RFS are unlikely to translate to overall survival in the salvage setting, one might advocate selecting the local salvage treatment with the lowest toxicity until randomized data are available," the authors wrote. (oncologynurseadvisor.com)
  • Studies examining the survival and toxicity of therapies administered to treatment-refractory pediatric MB patients will be included. (biomedcentral.com)
  • Among 79 patients who were given a total of 237 salvage treatments, median overall survival (OS) from the date of relapse post-CAR T-cell therapy was 17.9 months (95% CI 14.0 to not estimable [NE]), reported Samir Parekh, MD, of the Icahn School of Medicine at Mount Sinai in New York City, and colleagues. (medpagetoday.com)
  • The median progression-free survival (PFS) with the first attempted salvage therapy was 3.5 months. (medpagetoday.com)
  • This suggests that for eligible patients that progress after BCMA-directed CAR T, additional T-cell-engaging therapies contribute meaningfully to survival and that T-cell activation is feasible down the line," Parekh and team wrote. (medpagetoday.com)
  • Four-year survival and event-free survival estimates of 91% and 60%, respectively, together with a median postsalvage therapy survival of more than 5 years justify the conduct of a prospective randomized clinical trial to determine the clinical value of preemptive therapy in SMM. (elsevierpure.com)
  • Median intracranial progression-free survival of patients in the WBRT arm (10.4 months) was longer than that of patients in the salvage SRS arm (4.0 months). (elsevierpure.com)
  • It is therefore necessary to investigate the feasibility and efficacy of image guided permanent implantation of 125 I seeds as a salvage therapy for locally recurrent STS in children and to determine local control, survival, and complications. (biomedcentral.com)
  • Two phase 3 trials have compared SRT with and without androgen deprivation therapy (ADT), finding that combined treatment (SRT+ADT) improves both PFS and overall survival. (wjgnet.com)
  • For one of those patients, a survival of more than 836 days post-amrubicin therapy has been recorded. (cancernetwork.com)
  • We investigated the feasibility, efficacy, and morbidity of permanent interstitial 125 I seed implantation under image guidance as a salvage treatment for pediatric patients with recurrent or metastatic soft tissue sarcoma. (biomedcentral.com)
  • Four retrospective series assessed salvage treatments after FT failure evaluating cases of radical prostatectomy (RP) and repeat ablation (sample size from 12 to 22 patients). (endourology.ph)
  • Other options are radiation therapy (RT) and whole-gland or focal repeat ablations, although these have only been described after whole-gland ablation. (endourology.ph)
  • LP-irinotecan TACE was conducted in 42% of patients as salvage therapy, 20% as an intensification treatment, 16% as a first-line treatment, 14% a consolidation treatment and 8% combination treatment with ablation with curative intent. (springer.com)
  • Patients with multiple myeloma who relapse after treatment with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy can be salvaged with multiple lines of therapy, a retrospective study suggested. (medpagetoday.com)
  • Patients with multiple myeloma who relapse after BCMA-directed CAR T have a limited prognosis but can be potentially treated with multiple lines of salvage therapy," they wrote. (medpagetoday.com)
  • The 13 patients who received a T-cell-engaging therapy immediately after relapse on CAR T had an ORR of 75.0% and a median PFS of 9.1 months. (medpagetoday.com)
  • In a multicentre, single-arm, open-label phase 2 study, we enrolled adult patients with Philadelphia-chromosome-negative, primary refractory or relapsed (first relapse within 12 months of first remission, relapse within 12 months after allogeneic haemopoietic stem-cell transplantation [HSCT], or no response to or relapse after first salvage therapy or beyond) leukaemia. (nih.gov)
  • 12 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT. (nih.gov)
  • Regorafenib and TFTD+B are both standard salvage options for metastatic CRC. (mybestmedicine.com)
  • Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. (endourology.ph)
  • Image guided permanent interstitial 125 I seed implantation as a salvage treatment appears to have a satisfactory outcome in children with recurrent or metastatic soft tissue sarcoma. (biomedcentral.com)
  • Salvage therapy, in this context, is the attempt to contain the replicating HIV once the usual line of treatments have been exhausted. (wikipedia.org)
  • Patients received a median of two salvage treatments. (medpagetoday.com)
  • Furthermore, high-quality data on new minimally invasive salvage focal ablative treatments are needed. (ucl.ac.uk)
  • Novel predictive biomarkers are needed to identify men harboring micrometastatic disease to avoid potentially futile local therapies or allow for intensification of systemic therapies. (elsevierpure.com)
  • However, they suggested that prospective clinical trials are needed to evaluate the role of salvage transplant-based approaches. (medpagetoday.com)
  • Background Endovascular therapy has been shown to be effective in patients with acute cerebral large vessel occlusion, but real-world efficacies are unknown. (bmj.com)
  • We enrolled both consecutive patients who were treated with or without endovascular therapy. (bmj.com)
  • We constructed the matched cohort based on a propensity score for endovascular therapy and estimated the adjusted odds ratio [OR]. (bmj.com)
  • Results A total of 2420 patients were recruited, 2399 (1,278 in endovascular therapy vs 1121 in no endovascular therapy) provided the primary outcome at 90 days, and 2242 (1,121 each) propensity score matched cohort was analyzed. (bmj.com)
  • Favorable outcomes were observed in 35.3% and 30.7% of patients in the endovascular therapy and no endovascular therapy groups, respectively (p = 0.02). (bmj.com)
  • The efficacy of endovascular therapy in achieving favorable outcomes did not differ between our subgroups. (bmj.com)
  • Conclusions Endovascular therapy decreased disabilities at 90 days in real-world patients with acute cerebral large vessel occlusion. (bmj.com)
  • Of note, patients who received a T-cell-engaging therapy (a bispecific antibody or subsequent CAR T-cell therapy) had the greatest success in this setting, with OS not reached after a median follow-up of 21.3 months, they noted in Blood . (medpagetoday.com)
  • Achieving a partial response or better with the first line of salvage therapy was associated with a significantly longer median OS of 29.9 months compared with 14.6 months for patients who did not achieve an objective response ( P =0.028). (medpagetoday.com)
  • The 79 patients included in this analysis had a median age of 60 years at the time of progression after CAR T-cell therapy, and 60% were men. (medpagetoday.com)
  • For 33 evaluable patients, the median age was 66 and the median number of courses of therapy was 4. (cancernetwork.com)
  • The aim of this systematic review will be to investigate the efficacy and safety of salvage therapies for the management of children with progressive, treatment-refractory, or recurrent MB. (biomedcentral.com)
  • In 2010, the dilemma is not in the question of whether postprostatectomy adjuvant or salvage RT are effective among high-risk patients as a group, but rather which individual patients ought to receive it and when. (jnccn.org)
  • From March 2017 to January 2022, 140 patients with multiple myeloma were treated with a BCMA-directed CAR T-cell therapy on a clinical trial at either the Mount Sinai Tisch Cancer Institute or Memorial Sloan Kettering Cancer Center in New York City. (medpagetoday.com)
  • Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy. (elsevierpure.com)
  • Therefore, a systematic review of the literature regarding treatment strategies employed in recurrent pediatric MB will evaluate previous salvage therapies in order to guide future clinical trials. (biomedcentral.com)
  • Maggi JC, Nussbaum E, Babbitt C, Maggi FE, Randhawa I. Pediatric fiberoptic bronchoscopy as adjunctive therapy in acute asthma with respiratory failure. (springeropen.com)
  • A nonsystematic literature review in PubMed using the term "salvage radical prostatectomy" was performed on December 1, 2021. (unito.it)
  • The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. (facingourrisk.org)
  • Although often mentioned, but seldom used, men who fail radiation as a primary treatment can also benefit from salvage surgery. (malecare.org)
  • We performed a nonsystematic search of PubMed for articles assessing relevant outcomes for salvage local treatment after FT failure using a manual search. (endourology.ph)
  • Important limitations include the low level of the evidence and the absence of standardized criteria for FT, salvage treatment, and FT failure. (endourology.ph)
  • While it seems that FT has a minimal impact on salvage treatment results, prospective controlled studies are needed to confirm these preliminary data. (endourology.ph)
  • The authors performed a retrospective analysis of 28 patients who received multiple treatment lines and relapsed or did not achieve response after venetoclax-based salvage therapy. (hematologyadvisor.com)
  • 6 patients did not receive salvage treatment because of poor condition. (hematologyadvisor.com)
  • As there was no response to the abovementioned line of treatment, other nonstandard therapies such as intramuscular adrenaline and ketamine were also tried but to no avail. (springeropen.com)
  • Posaconazole can be used off-label for salvage treatment in patients intolerant to amphotericin B. It has also been used as step-down therapy after initial control of the disease with amphotericin. (medscape.com)
  • ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non-small-cell lung cancer. (cancernetwork.com)
  • Intraoperative electron radiation therapy after salvage surgery in gynecological cancers and retroperitoneal sarcomas: outcomes and adverse effects. (bvsalud.org)
  • Secondary outcomes will include safety and toxicity of each therapy administered. (biomedcentral.com)
  • By reviewing the efficacy and toxicity of MB salvage therapies, this study will identify effective therapeutic strategies administered to recurrent MB patients and can inform future clinical trials aimed to improve patient survivorship and quality of life. (biomedcentral.com)
  • Investigation of clinically tested therapies for children with recurrent MB has significant implications for clinical practice. (biomedcentral.com)
  • Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion (SOCCER), aiming to evaluate the effect of oxygen therapy on myocardial salvage and infarct size in patients with ST elevation myocardial infarction (STEMI) treated with a primary percutaneous coronary intervention (PCI). (lu.se)
  • In additional analyses, we will investigate the role of re-irradiation and mono- vs. poly-therapy in recurrent disease, and whether molecular subgrouping of MB influences salvage therapy. (biomedcentral.com)
  • I often discuss the use of salvage radiation after surgery has failed and the PSA begins to rise. (malecare.org)
  • Methods: Fifty-nine patients treated in the Breast Surgery Unit at the University Hospital of Parma (Italy) between January 2010 and December 2017 for ipsilateral breast recurrent cancer, previously treated by partial mastectomy plus whole-breast radiation therapy, were analyzed. (unipr.it)
  • Patients were randomly assigned to WBRT or salvage SRS arms within 21 days of surgery. (elsevierpure.com)
  • We evaluated the outcomes and adverse effects in patients with retroperitoneal sarcoma and gynecologic tumors after salvage surgery and IOERT. (bvsalud.org)
  • A strength of the study was the comprehensive inclusion of both surgical and nonsurgical local salvage modalities as well as clear distinctions among the types of salvage brachytherapy and external beam radiation therapy, the authors noted. (oncologynurseadvisor.com)
  • Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have shown the therapeutic efficacy of BNCT for head and neck cancer. (neuboron.com)
  • Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. (drzarirudwadia.com)
  • This study evaluated the safety and efficacy of switching HIV-infected patients with stable viral suppression on nonnucleoside reverse transcriptase inhibitor/nucleoside reverse transcriptase inhibitor (NNRTI/NRTI) therapy to lopinavir/ritonavir (LPV/r) monotherapy. (researchgate.net)
  • Nevertheless, the question of whether all patients with the aforementioned adverse features should undergo immediate adjuvant RT versus initial observation with more selective-but early-salvage RT in the event of biochemical failure remains the subject of heated controversy. (jnccn.org)
  • The benefit of combination therapy with different classes of antifungals (including echinocandins) is uncertain. (medscape.com)
  • Dr. Baselga, of Vall D'Hebron University Hospital, Barcelona, Spain, reported phase II data from a multicenter, international, randomized, double-blind, parallel-group study of two different dosages of the investigational EGFR tyrosine kinase inhibitor ZD-1839 (Iressa) as salvage monotherapy for patients with advanced NSCLC. (cancernetwork.com)
  • This systematic review will provide an overview of the current literature regarding salvage therapies for relapsed MB patients. (biomedcentral.com)
  • Current evidence shows acceptable outcomes for post-FT salvage options, although this is based on retrospective data. (endourology.ph)
  • Conclusions: The possibility of initiating salvage therapy earlier is discussed, potentially based on improved future biomarker panels. (lu.se)
  • These methods and results can help us to better understand immune reconstitution following hematopoietic cell transplantation, leading to future studies on the clinical application of adoptive T-cell therapies. (nature.com)
  • A better and deeper understanding of immune reconstitution following allo-HCT is required for further clinical application of these adoptive T-cell therapies. (nature.com)
  • Second, F1CDx lacks randomized data showing superiority to the current strategy of selecting a salvage therapy based on histopathology and clinical considerations. (medscape.com)
  • When at least one regimen containing protease inhibitors has failed in a patient, the subsequent attempts to treat the HIV infection may be referred to as salvage therapy. (wikipedia.org)
  • However, targeted therapies did not induce object responses in the patient population analyzed. (hematologyadvisor.com)
  • abstinence) prior to study entry, for the duration of study participation, and for 4 months following completion of therapy. (uci.edu)
  • The Effects of Oxygen Therapy on Myocardial Salvage in ST Elevation Myocardial Infarction Treated with Acute Percutaneous Coronary Intervention: The Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion (SOCCER) Study. (lu.se)
  • Dr. Spiess' research interests include novel therapies for advanced renal, bladder and penile cancer. (moffitt.org)
  • Salvage therapy, also known as rescue therapy, is a form of therapy given after an ailment does not respond to standard therapy. (wikipedia.org)
  • Bronchoscopy as a rescue therapy in patients with status asthmaticus: two case reports and review of literature. (springeropen.com)
  • Nucleoside analogs such as fludarabine or cladribine pose a risk of stem cell damage and leukemogenesis and should not be used as initial therapy in patients who are candidates for stem cell transplantation (SCT). (medscape.com)
  • In order to increase local control intra operative electron radiation therapy (IOERT) can be used in these patients to administer additional radiation dose . (bvsalud.org)
  • [ 3 ] Corticosteroids are used as adjunctive initial therapy only in patients with HIV infection who have severe PJP. (medscape.com)